<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>abbreviations of medicines</td>
<td>35.5</td>
</tr>
<tr>
<td>ABC analysis</td>
<td></td>
</tr>
<tr>
<td>in Asian countries</td>
<td>40.16, 40.18</td>
</tr>
<tr>
<td>of expenditures</td>
<td>40.13–40.19</td>
</tr>
<tr>
<td>in procurement</td>
<td>18.15</td>
</tr>
<tr>
<td>in supply strategies</td>
<td>40.19</td>
</tr>
<tr>
<td>ABC/FS system</td>
<td>23.15</td>
</tr>
<tr>
<td>absolute monopolies</td>
<td>9.4</td>
</tr>
<tr>
<td>access to medicines</td>
<td></td>
</tr>
<tr>
<td>acceptability</td>
<td>1.8–1.9</td>
</tr>
<tr>
<td>affordability</td>
<td>1.8–1.9</td>
</tr>
<tr>
<td>assessing</td>
<td>1.11–1.12</td>
</tr>
<tr>
<td>availability</td>
<td>1.8–1.9</td>
</tr>
<tr>
<td>challenges in</td>
<td>1.12–1.18</td>
</tr>
<tr>
<td>consumer products vs.</td>
<td>1.5</td>
</tr>
<tr>
<td>costs of</td>
<td>1.4–1.6</td>
</tr>
<tr>
<td>defining</td>
<td>1.8</td>
</tr>
<tr>
<td>distribution management in</td>
<td>1.11</td>
</tr>
<tr>
<td>economic goals</td>
<td>1.8</td>
</tr>
<tr>
<td>efficiency of</td>
<td>1.13–1.16</td>
</tr>
<tr>
<td>essential medicines concept in</td>
<td>1.7–1.8</td>
</tr>
<tr>
<td>financial sustainability and</td>
<td>1.12</td>
</tr>
<tr>
<td>financing strategies for</td>
<td>11.13</td>
</tr>
<tr>
<td>globalization of</td>
<td>3.3–3.10</td>
</tr>
<tr>
<td>glossary terms</td>
<td>3.21</td>
</tr>
<tr>
<td>governance and</td>
<td>1.10–1.11, 1.13–1.16</td>
</tr>
<tr>
<td>governments and</td>
<td>1.17</td>
</tr>
<tr>
<td>health-related goals</td>
<td>1.8</td>
</tr>
<tr>
<td>history of</td>
<td>2.2–2.3</td>
</tr>
<tr>
<td>as human right</td>
<td>3.5, 4.14</td>
</tr>
<tr>
<td>indicators of</td>
<td>36.11</td>
</tr>
<tr>
<td>insurance benefits for</td>
<td>12.11</td>
</tr>
<tr>
<td>intellectual property and</td>
<td>3.3–3.10</td>
</tr>
<tr>
<td>lack of support systems for</td>
<td>2.7</td>
</tr>
<tr>
<td>monitoring</td>
<td>1.11–1.12</td>
</tr>
<tr>
<td>national development goals in</td>
<td>1.8</td>
</tr>
<tr>
<td>national medicine policies and</td>
<td>1.8–1.9, 4.14</td>
</tr>
<tr>
<td>public health objectives for</td>
<td>1.7–1.8</td>
</tr>
<tr>
<td>rational medicine use and</td>
<td>1.11–1.12</td>
</tr>
<tr>
<td>registration and regulation in</td>
<td>1.18, 3.12–3.14</td>
</tr>
<tr>
<td>selecting medications in</td>
<td>1.10</td>
</tr>
<tr>
<td>traditional medicine in</td>
<td>5.4, 5.8, 5.12</td>
</tr>
<tr>
<td>accountability</td>
<td></td>
</tr>
<tr>
<td>in health facilities</td>
<td>46.4</td>
</tr>
<tr>
<td>in human resources management</td>
<td>51.16</td>
</tr>
<tr>
<td>in national medicine policies</td>
<td>4.14</td>
</tr>
<tr>
<td>accounting</td>
<td></td>
</tr>
<tr>
<td>computer use for</td>
<td>50.6</td>
</tr>
<tr>
<td>in financial management</td>
<td>41.17–41.19</td>
</tr>
<tr>
<td>in health services contracts</td>
<td>39.15</td>
</tr>
<tr>
<td>accounts payable and receivable</td>
<td>21.20, 41.18</td>
</tr>
<tr>
<td>accredited drug-dispensing outlets (ADDOs)</td>
<td></td>
</tr>
<tr>
<td>for access to medicines</td>
<td>1.16</td>
</tr>
<tr>
<td>in Tanzania</td>
<td>32.6–32.9, 32.13–32.14</td>
</tr>
<tr>
<td>acquisition of medicines</td>
<td>See procurement of pharmaceuticals</td>
</tr>
<tr>
<td>acquisition of storage facilities</td>
<td>42.8</td>
</tr>
<tr>
<td>ACT. See artemisinin-based combination therapy</td>
<td></td>
</tr>
<tr>
<td>Action Programme on Essential Drugs (WHO)</td>
<td>36.16–36.17</td>
</tr>
<tr>
<td>active data collection</td>
<td>35.10</td>
</tr>
<tr>
<td>activity-time charts</td>
<td>38.14</td>
</tr>
<tr>
<td>ACT UP (AIDS Coalition to Unleash Power)</td>
<td>2.7, 31.3</td>
</tr>
<tr>
<td>ADDOs. See accredited drug-dispensing outlets</td>
<td></td>
</tr>
<tr>
<td>adherence to treatment</td>
<td></td>
</tr>
<tr>
<td>complexity and duration of treatment</td>
<td>33.8</td>
</tr>
<tr>
<td>determinants of</td>
<td>33.9–33.10</td>
</tr>
<tr>
<td>introduction to</td>
<td>33.4–33.9</td>
</tr>
<tr>
<td>adjudicating tender</td>
<td>21.15–21.18</td>
</tr>
<tr>
<td>adjusted consumption method</td>
<td>18.5, 47.9</td>
</tr>
<tr>
<td>adjusting final quantities</td>
<td>20.13–20.15</td>
</tr>
<tr>
<td>adverse drug events (ADEs)</td>
<td>35.5–35.6, 35.13. See also pharmacovigilance</td>
</tr>
<tr>
<td>adverse drug reactions (ADRs)</td>
<td>data on, 29.4</td>
</tr>
<tr>
<td>monitoring</td>
<td>6.9</td>
</tr>
<tr>
<td>in pharmacovigilance</td>
<td>35.3–35.4</td>
</tr>
<tr>
<td>quality assurance vs.</td>
<td>19.7</td>
</tr>
<tr>
<td>reporting</td>
<td>35.15</td>
</tr>
<tr>
<td>adverse selection (in insurance)</td>
<td>11.11, 12.6</td>
</tr>
<tr>
<td>advertising</td>
<td>6.10</td>
</tr>
<tr>
<td>advocacy groups</td>
<td>2.7, 31.3. See also community participation</td>
</tr>
</tbody>
</table>
affordability
  in national medicine policies, 4.7, 4.9
  of products and services, 1.8–1.9
  of traditional medicine, 5.4
Afghanistan, 31.7, 45.6
African countries
  adherence to ART in, 28.10
  Bamako Initiative in, 31.9
  community-based health insurance in, 12.13
  counterfeit medicines in, 19.9
  health facility medicine use in, 28.8
  health insurance in, 12.16
  HIV/AIDS treatment in, 18.10
  human resources in, 51.10
  NGO essential medicines services in, 8.15
  pharmaceutical production in, 7.5
  price of services in, 41.3
  registration of medicines in, 6.13
  retail drug seller education in, 32.4
  RxSolution in, 50.12
  scaling up ART in, 20.8
  supply management training in, 52.15
  training networks in, 52.13
  TRIPS flexibilities in, 3.11
  voluntary licensing in, 3.9
aggregation of data, 28.4, 28.9–28.11
aggregation of demand, 18.13
AIDS Coalition to Unleash Power. See ACT UP
AIDS Medicines and Diagnostics Service (WHO), 2.6
AIDS Research Alliance, 5.14
AIDS treatment. See HIV/AIDS treatment
air waybills, 24.7–24.8
allocative efficiency, 10.9–10.10, 11.3
Alma Ata Declaration of 1978, 31.2
alphabetizing stock, 44.13
alternative distribution channels, 6.13–6.14
alternative medicine. See traditional medicine (TM)
American Hospital Formulary Service (AHFS), 16.10,
  40.21
American Society of Health-System Pharmacists, 45.4
AMR. See antimicrobial resistance
Anatomical, Therapeutic, and Chemical (ATC)
  classifications, 16.13, 28.4, 40.21
annual purchasing, 23.12–23.13, 23.15
annualized capital costs, 10.13
antibiotics
  health facilities' use of, 28.9
  rational prescribing, 29.5, 29.12–29.16
  reviewing use of, 29.16
  standard treatment guidelines and, 29.8
antimalarials, 33.16. See also artemisinin-based
  combination therapy (ACT)
antimicrobial resistance (AMR)
in Kenya, 40.15
  prevalence, 27.6
  rational medicine use vs., 27.5–27.6, 27.14
antiretroviral therapy (ART)
  adherence to treatment in, 28.10, 33.4
  assessing management of, 36.4–36.5
  in Brazil, 9.9
  computer use in, 50.14
  controlling theft of, 43.3
  costs of, 1.13, 9.9
  effectiveness of, 1.5
  Electronic Dispensing Tool for, 49.6
  history of, 2.6
  human resources crisis and, 51.2–51.7, 51.12–51.16
  in Kenya, 30.4, 37.17, 48.4–48.5, 51.6
  medication counseling for, 33.6
  and pharmacovigilance, 35.9
  pricing of, 9.9, 9.11
  quantifying pharmaceutical requirements for, 20.8
  in Rwanda, 17.15
  in South Africa, 46.11
  in Uganda, 47.3
  voluntary licensing and, 3.9
antiretrovirals (ARVs). See antiretroviral therapy (ART)
appeal periods (in tendering), 21.18
appropriate medicine use by consumers. See consumer use
  of medicines
appropriate use of medicines. See rational medicine use
Arab countries, 28.11
ARI (acute respiratory infection), 17.9
ART programs. See antiretroviral therapy (ART)
artemisinin-based combination therapy (ACT)
costs of, 1.13
  effectiveness of, 1.10
  problems with, 2.6
  and rational medicine use, 27.6
  rational use of, 33.14
ARVs (antiretrovirals). See antiretroviral therapy
  (ART)
Asian countries
  ABC analysis in, 40.16, 40.18
  counterfeit medicines in, 19.9
  health facility medicine use in, 28.8
  tablet and capsule embossing in, 43.7
  transparency assessments in, 36.12
  TRIPS flexibilities in, 3.11
assessments
  in pharmaceutical management planning, 38.7–38.9
  in pharmaceutical procurement, 18.11
  in pricing policies, 9.15–9.16
  of retail drug outlets, 28.18
ATC. See Anatomical, Therapeutic, and Chemical (ATC)
classifications
  audits, 18.12, 18.16, 35.12
Australia

choosing standard treatments in, 17.8
national medicine policies in, 4.16
Pharmaceutical Advisory Council in, 4.16
pharmaceutical benefits scheme in, 9.7
pharmaco-economics in, 10.8
rural pharmacy program of, 51.5–51.6
treatment guidelines in, 17.5
Australian Prescriber, 34.6
automated medication dispensing, 45.9
autonomous supply agencies, 8.7–8.10, 18.16
availability. See also access to medicines
in inventory management, 23.7
of medicines and supplies, 31.5
of products and services, 1.8–1.9
average consumption, 23.16
average cost per unit, 10.13
average inventory-holding costs, 23.6
balance sheets, 41.18–41.19
Bamako Initiative, 31.3, 31.9
bank guarantees, 24.7
bar coding, 19.15
Basic Support for Institutionalizing Child Survival
(BASICS), 1.17, 31.12, 32.4, 32.14
Basic Surgical Instruments Supply Kit, UNICEF, 47.8
batch certificates, 19.13
batch number registration, 43.7
benchmarks, in drug use review, 29.11–29.12, 29.14
Benin, 31.9
best practices
for donor financing, 14.4
for management, 37.6–37.11
for retail drug sellers, 32.5–32.7
BIAC. See Business and Industry Advisory Committee to
the OECD
bilateral agencies, 14.5
bilateral donors, 14.8
bilateral trade agreements, 3.13
Bill & Melinda Gates Foundation. See Gates Foundation
bills of lading, 24.7–24.8
bin cards, 23.4
bioavailability, 19.4–19.5
Biopharmaceutical Classification System, 19.5
BNF. See British National Formulary
Bolar exception, 3.7, 3.12
Bolivia, 12.6–12.8
Bosnia, 15.4
bottom-up management approach, 13.12, 38.5–38.6
brand premiums, 9.18
branded off-patent medicines, 9.9–9.10
brand-name drugs, 17.13
Brazil
access indicators in, 36.11
diarrhea treatment in, 28.17
information management in, 49.13
medication counseling in, 30.9
pricing policies in, 9.9
break-even analysis, 41.9
bribery control, 43.9–43.11
British National Formulary (BNF)
on CD-ROM, 50.16
essential medicines lists in, 16.7, 16.10, 16.13
on PDAs, 17.14, 50.9
treatment guidelines in, 17.3
British Pharmacopoeia, 19.8
budgets
for building storage facilities, 42.8–42.9
for facilities, 29.15
in financial management, 41.10–41.12
gap analysis in, 11.10
of governments, 11.7–11.10
in health services contracts, 39.15
and inventory management, 23.18
for laboratory services, 47.4
operating, 41.16
per capita, 11.10
performance reports on, 41.17
requirements for, 20.4
service-level projections for, 20.4–20.5, 20.26–20.28
template for, 48.18
transfers in, 12.8
building storage facilities. See storage facilities
bulk storage, 46.3, 46.4
Buscando remedio (treatment guidelines, Nicaragua), 17.5
business ethics, 32.12
Business and Industry Advisory Committee to the OECD
(BIAC), 3.17
buyer strategies to decrease prices, 9.14–9.17
CAM (complementary and alternative medicine). See
traditional medicine (TM)
Cambodia
access indicators in, 36.11
health services contracts in, 39.12
kit systems in, 26.14
medication counseling in, 30.9
supply of medicines in, 26.14
tuberculosis treatment in, 31.14
Canada, 50.9
capacity
of staff. See human resources management (HRM)
in supply strategies, 8.17
training programs for, 52.3
capacity-building framework, 52.3
capital costs, 10.13
capitalization requirements, 13.9–13.10
capitation
  payments, 12.7–12.8
  reimbursements based on, 29.17
  systems, 9.19
capsule imprinting, 43.7
cardiocirculatory diseases, 1.5
career development, 44.17, 51.20
CAREshops (Ghana), 1.16, 32.9
Caribbean countries
  health facility medicine use in, 28.8
  health insurance in, 12.16
  oral vs. injectable antibiotics in, 29.13
  scheduled purchasing in, 23.14
  TRIPS flexibilities in, 3.11
carriage and insurance paid (CIP), 21.7, 21.16, 39.5
carrying costs, 22.16
case payments, 12.8
case records review, 28.11–28.12
cash planning, 41.12–41.14
categories of pharmaceuticals, 3.3
CD-ROMs, 50.16–50.18
Center for Pharmaceutical Management (CPM), 36.7
centers for medicine information. See medicine information
central medical stores (CMS)
  balance sheets for, 41.19
  in financial planning, 41.3–41.7
  government vs. RDF budgets in, 41.5
  income and expense reports for, 41.18
  introduction to, 1.15
  managing. See medical stores management
in Namibia, 44.3
  operating budgets for, 41.16
  price structure in, 41.11
  procurement for, 18.16
  in supply strategies, 8.7
  in Zimbabwe, 25.15
certificates of origin (COs), 24.7
certificates of quality (CQs), 24.7
certification of products, 19.10–19.14
change management, 37.15–37.20, 38.7
children
  BASICS for, 1.17
  C-IMCI for, 31.6
  and consumer use of medicines, 33.5
  drug management for, 28.12, 31.11–31.12
  health services for, 12.7
  health services for mothers and, 1.5, 12.7
  PMTCT for, 20.9
  treatment for, 31.6, 31.12
  UNICEF and. See UNICEF
Chile, 27.11
chloramphenicol, 2.2–2.3
chloroquine, 2.2
chlorpromazine, 2.2
cholera treatment, 20.6
chronic diseases, 1.5
CIF (cost, insurance, and freight), 18.24, 21.7, 21.16, 39.5
C-IMCI (Community Integrated Management of Childhood Illness), 31.6
CIP. See carriage and insurance paid
classification
  Anatomical, Therapeutic, and Chemical, 28.4
  of biopharmaceuticals, 19.5
  of cases, 28.6
  of diseases, 20.19, 28.6
  of medical store stock, 44.12–44.13
  of pharmaceuticals, 6.13
  Pharmacologic-Therapeutic, 40.21
  of therapeutics, 16.10–16.13
clearing agents, 24.3–24.4
climatic factors, 22.12, 22.14
clinical evidence, 17.6
clinical guidelines. See treatment guidelines
  clinical newsletters, 29.9
  clinical triggers, 35.11
collating tender offers, 21.15–21.16
commercial terms, 39.7
Commission on Intellectual Property Rights, Innovation and Public Health, 3.17
commissioning storage facilities, 42.16–42.17
committees
  for medicine selection. See drug and therapeutics
  committees (DTCs)
national medicine, 40.12
commodities
  codes for, 44.13–44.15
  in donor financing, 14.10
communication with consumers. See also communications
  behavioral theory in, 33.20
  commercial interests and, 33.20
  constraining factors in, 33.20–33.21
  cultural factors in, 33.21
by drug-dispensing outlets, 33.9
  education campaigns for, 33.19–33.20
  factors influencing, 33.18–33.21
  information technology and, 33.20
infrastructure for, 33.20
interventions in, 33.14–33.18
  mass media and, 33.20
on medicine use, generally, 33.10
on medicine-use problems, 33.12–33.14
methods for, 33.22
neighbor-to-neighbor, 33.16
new prescription information, 33.15
plans for, 33.18
policies for, 33.20
principles of, 33.10–33.11
professional interests and, 33.20
provider-patient, 33.4–33.6
for revolving drug funds, 13.18–13.19
social factors in, 33.20–33.21
social marketing and, 33.14
strategies for, 33.11–33.18
communications
with consumers. See communication with consumers
in distribution management, 22.16
in management information systems, 49.12
in medical stores, 44.4–44.5
in monitoring and evaluation, 48.12
in procurement, 18.19–18.20
in program management, 37.14
community-based health insurance
in Africa, 12.13
overview of, 12.12–12.15
pharmaceutical benefits in, 12.4
in Uganda, 12.15
community-based organizations, 2.7
Community Drug Management for Childhood Illness
(C-DMCI), 28.12, 31.11–31.12
Community Health Fund (CHF) (Tanzania), 12.12
community health workers (CHWs), 31.5–31.9, 32.10, 46.12
Community Integrated Management of Childhood Illness
(C-IMCI), 31.6
community participation
access to medicines via, 31.5
case management and, 31.7
childhood illness treatment via, 31.6, 31.12
environments enabling, 31.14–31.15
facility-based health services and, 31.7–31.8
health professionals and, 31.10
health programming and, 31.10–31.14
investigating medicine use via, 28.13–28.14
meaning of, 31.3–31.4
monitoring health services via, 31.13–31.14
needs assessments via, 31.10–31.11
organization of, 31.13
outreach services and, 31.5–31.7
pharmaceutical management and, 31.5–31.9
planning of, 31.13
pneumonia treatment and, 31.8
preventive health care and, 31.5
rational medicine use and, 27.8, 31.8–31.9
in revolving drug funds, 13.12–13.13
comparative costs (in contracting), 39.12–39.13
comparative expenditure analysis, 11.10
comparative pricing, 13.15
comparison
data, 48.19
of financing strategies, 11.13–11.15
groups, 28.20
in pharmaco-economic analysis, 10.11
of supply strategies, 8.13–8.14
competition
failure of, 8.5
in market-based economies, 9.3–9.6, 10.5
in negotiations, 18.7, 18.12–18.14, 21.16
complementary and alternative medicine (CAM). See traditional medicine (TM)
Comprehensive Plan for the Treatment and Care of HIV and AIDS (South Africa), 46.11
compulsory licensing, 3.6–3.8, 3.12
computer use
for accounting, 50.6
in antiretroviral therapy, 50.14
data analysis via, 50.11
data protection, 50.17–50.18
databases, 50.6
for desktop publishing, 50.6
drug use reviews via, 50.14
e-communications via, 50.14–50.16
for financial reports, 50.13
formulary manuals and, 50.11
functional lists/outputs via, 50.13
geographic information via, 50.8
glossary terms, 50.21–50.23
in Haiti, 50.14
hardware, 50.8
for information management, 49.11–49.12
inventory management via, 50.11, 50.13
local area networks for, 50.3, 50.7
maintenance of, 50.16–50.18
manual systems vs. for quantification, 20.9–20.10
for medicine information, 50.14–50.16
multilocation reports via, 50.13
onboard transport vehicles, 25.10
order reports via, 50.13
for periodic analyses, 50.4
pharmaceutical management via, 50.3, 50.18
pharmacy management via, 50.11
for presentations, 50.6
procurement via, 50.11
product master files, 50.22–50.24
product registration via, 50.14
product reports via, 50.13
quantifying pharmaceutical requirements via, 50.9–50.11
for referral systems, 46.11
sales reports via, 50.13
software for. See software
for spreadsheets, 50.6
staff for, 50.16–50.17
for statistics, 50.6
tender reports via, 50.13
utility programs for, 50.7
website development in, 50.16–50.17
wide area networks for, 50.7
for word processing, 50.6

Conference of Experts on the Rational Use of Drugs, 27.2
consignments, 24.7–24.8
construction of storage facilities, 42.13–42.17
consultants, 14.16–14.17, 42.5
consumables kits, 47.9
consumer use of medicines. See also rational medicine use
adherence to treatment in, 33.4–33.10
assessment guide for, 33.23
availability of information and, 33.8–33.9
children and, 33.5
communications for. See communication with consumers
complexity and duration of treatment in, 33.8
counseling and, 33.6
DOTS strategy for, 33.8, 33.11
enablers in, 33.11
in health care facilities, 33.9
incentives for, 33.11
lack of resources and, 33.6–33.8
need for encouraging, 33.2–33.4
organizations related to, 33.24–33.25
pictograms on labels for, 33.25
prepackaging of medicines in, 33.10
problems in, 33.3
provider-patient communications on, 33.4–33.6
in TB treatments, 33.8
consumers
communications with. See communication with consumers
education posters for, 33.9
ignorance and uncertainty of, 12.6
interviews of, 28.13
opinions of, 13.15, 13.19
organizations of, 27.13, 29.4
products for, 1.5
use of medicine by. See consumer use of medicines
consumption method
adjusted, 47.9
cross-checking results in, 20.12–20.13
for quantifying pharmaceutical requirements, 20.3–20.5, 20.15–20.18
reordering formulas in, 23.20–23.21
reporting in, 22.5–22.6
contracting for health services. See also contracting for pharmaceuticals
accounting in, 39.15
budgets in, 39.15
in Cambodia, 39.12
communications in, 39.16
comparative costs in, 39.12–39.13
cost analysis in, 39.13
development in, 39.14–39.16
duration of contracts in, 39.15
feasibility assessment for, 39.11–39.14
grounds for termination in, 39.15
health system indemnity in, 39.15
insurance in, 39.16
management of, 39.15
monitoring contracts in, 39.16
noncompliance penalties in, 39.15
overview of, 39.2–39.3
payment terms in, 39.15
performance indicators in, 39.14, 39.15
pharmacy benefits in, 39.3
private-sector capacity in, 39.13–39.14
property rights in, 39.15
provider qualifications in, 39.14
reporting in, 39.15
review procedures in, 39.15
scope of service in, 39.15
staffing in, 39.15
in supply strategies, 8.13
contracting for insurance, 12.5
contracting for pharmaceuticals. See also contracting for health services
bid bonds in, 39.9–39.10
commercial terms in, 39.7
currency in, 39.6–39.7
default penalties in, 39.10
deferred payment in, 39.7
in distribution management, 22.17
exchange rates in, 39.6
experience in, 39.10
expiry dates in, 39.9
feasibility assessment for, 39.11–39.14
financial capability in, 39.6
labeling and nomenclature in, 39.8
letters of credit in, 39.7
manufacturing approvals in, 39.8
packaging in, 39.8–39.9
patent provisions in, 39.10
payment terms in, 39.7
performance bonds in, 39.9–39.10
pharmacy benefit programs in, 39.3
price comparisons in, 39.6
price validity in, 39.7
purchase quantities in, 39.6
quality assurance in, 19.14–19.15
quality standards in, 39.7–39.8
shelf life in, 39.9
shipment dates in, 39.10
in tender management, 21.18
terms in, 39.3–39.11
trade terms in, 39.5–39.6
contracting for storage facilities, 42.15
contraindications, in standard treatment guidelines, 17.7
controlled environments for storage, 46.5
controlled substances, 45.10–45.12, 46.5–46.6
controlling demand, 11.3
controlling pharmaceutical expenditures. See expenditures for pharmaceuticals
coordinated informed buying, 18.11
co-packaging, 19.18
co-payment, 12.7, 12.9–12.10
corrosives, 46.6
corruption, 1.6, 1.13–1.14, 4.6, 4.8, 4.17–4.18, 6.10, 8.17, 10.9, 11.9, 36.12, 43.13
COs. See certificates of origin
cost analysis
in distribution management, 22.16–22.17
in expenditures for pharmaceuticals, 40.2–40.3
in financial planning, 41.9
in health services contracts, 39.13
of laboratory supplies, 47.12
cost, insurance, and freight (CIF), 21.16
Costa Rica, 40.8
cost-benefit analysis (CBA)
in pharmaceutical management, 10.11, 10.12
in planning, 38.10
of security efforts, 43.12
cost-effective distribution systems, 22.3
cost-effectiveness analysis (CEA), 10.11–10.14, 17.8
cost-minimization analysis (CMA), 10.11
cost-recovery, 13.7–13.8, 13.16
costs
bar graphs of, 29.15
creating gap in access to medicines, 2.2–2.3
escalation of, 11.11, 12.6
in financial management, 41.9–41.10
information on, 29.13–29.14
of kit systems, 26.8–26.9
of medicines, 1.4–1.6
of medicines in insurance, 12.9–12.11
in pharmaceutical management, 10.10–10.14
in procurement of pharmaceuticals, 18.5–18.6
rational medicine use and, 27.6
in revolving drug funds, 13.10
of security management, 43.12–43.13
in storage facility construction, 42.5–42.6
in supply strategies, 8.17
of supply systems assessment, 36.8
of transportation, 22.14
of treatments, 17.7–17.8
cost-utility analysis, 10.11–10.12
COT packages. See course-of-therapy (COT) packages
counseling, 33.6. See also education
counterfeit medicines
in African countries, 19.9
in Asian countries, 19.9
legislation on and regulation of, 6.14–6.15
quality assurance vs., 19.9
in the United States, 19.9
WHO on, 19.9
course-of-therapy (COT) packages
in dispensing practices, 30.13–30.14
expenditures for, 40.21–40.24
fees for, 13.14
in hospital pharmacies, 45.12–45.13
in rational prescribing, 29.17
in revolving drug funds, 13.14
CPM. See Center for Pharmaceutical Management
CQs. See certificates of quality
crisis management, 37.5, 38.7
critical path method analysis, 38.17–38.18
Croatia, 3.19, 15.4
cross-contamination, 30.3
currency exchange, 18.22
cyclic counting, 23.5
DALY. See disability-adjusted life-year
dangerous drugs, 45.10–45.12
Dangerous Drugs Act (DDA), 45.10
data
aggregation of, 28.4, 28.9–28.11
analysis of. See data analysis
in management information systems, 49.4, 49.7–49.11, 49.15
on medicine use, 28.4–28.6
in pharmacovigilance, 35.10–35.12
protection of, 3.7–3.9, 3.12, 50.17–50.18
qualitative vs. quantitative, 36.14
for rational prescribing, 29.11–29.12
on supply systems, 36.17–36.18
data analysis
in assessing supply systems, 36.18–36.19
computer production of, 50.11
in pharmacovigilance, 35.11–35.15
Data Sheet Compendium, 34.8
databases, 50.6, 50.22–50.24
DDDs. See defined daily doses
Debt Relief Initiative, 14.11
decapitalization, 13.21
decentralization of supply system, 8.16–8.18
default penalties in contracts, 39.10
I.8  INDEX

defered payments in contracts, 39.7
defined daily doses (DDDs)
in COIs, 40.24
in investigating medicine use, 28.10–28.11
in rational prescribing, 29.4
by WHO, 40.21
delivery
collection systems vs., 22.13–22.14
cost of, 23.18
direct systems for, 1.15, 8.10, 18.16
intervals of, 26.13–26.14
in purchasing contracts, 21.6–21.7
schedules for, 22.14, 26.12–26.13
of supplies, 22.5–22.6
vouchers for, 44.24
demand and supply
in inventory management, 23.7
in pricing policies, 9.2–9.3
in revolving drug funds, 13.13
Democratic Republic of Congo, 31.7
Department of Essential Medicines and Pharmaceutical Policies (WHO), 2.8
dependent demand systems, 23.4
design
desktop publishing, 50.6
of interventions, 28.17–28.18
of pharmacovigilance systems, 35.6–35.10
of program management systems, 37.16
of storage facilities, 42.5, 42.9–42.14
of treatment guidelines, 17.14
deterioration costs, 40.6
determinants of quality, 19.6–19.7
developing countries
accredited drug-dispensing outlets in, 32.6–32.9
financing strategies in, 11.5–11.6
national medicine policies of, 4.5
R&D for new medicines in, 3.19–3.20
retail drug sellers in. See retail drug sellers
training programs in, 52.10
TRIPS and, 3.6, 3.10
development
donor financing for, 14.3–14.5
loans for, 11.7, 11.12–11.13
devolution in supply systems, 8.17
dgMarket, 21.10
diagnostic commodities, 47.6–47.7
diagnostic criteria, 17.7
diagnostic guidelines, 47.6
diagnostic kits, 47.9
diarrhea treatment
financing of, 12.7
guidelines for, 17.3–17.4
investigating use of, 28.6, 28.11–28.13, 28.17
mortality rates vs., 2.11, 11.9
pharmaceutical requirements for, 20.23
rational use in, 27.4–27.5, 27.10–27.11
sentinel reporting for, 48.5
digressive markups, 9.19
Diocesan Hospital Pharmacies (DHPs) (Ghana), 45.14
direct costs, defined, 41.9
direct delivery (non-CMS) systems
introduction to, 1.15
in procurement, 18.16
in supply strategies, 8.10
direct observation, 35.11
direct requisition systems, 26.13
directly observed treatment, short course. See DOTS
disability–adjusted life-year (DALY), 10.12
disaster relief
in earthquakes, 26.4
for emergencies, 20.5
for Indian Ocean tsunami, 15.7, 26.4
discrepancy reports, 46.10
dispensed selling prices, 9.11–9.12
dispensers, attributes of, 30.3–30.5
dispensing practices
accuracy vs. speed in, 30.10
COIs in, 30.13–30.14
counters in, 30.14
counting tablets/capsules in, 30.7, 30.14
in developing countries. See retail drug sellers
in distribution cycle, 22.5–22.6
electronic tablet counters in, 30.14
environment impacting, 30.2–30.3
factors influencing, 30.12
inspection checklist for, 30.11
labeling in, 30.3, 30.6–30.7, 30.12–30.13
limitations in, 29.20–29.21
management of, 30.10–30.11, 49.6
packaging in, 30.8, 30.11–30.12
pan weighing scales in, 30.14
patient counseling and, 30.8–30.10
pharmacy personnel in, 30.14–30.16
precautions in, 30.14
prescriptions in, 30.5–30.6
process of, 30.5–30.10
quality assurance in, 19.18, 30.14
rational medicine use and, 27.7–27.8
rational prescribing in, 29.15
record keeping in, 30.7
stock containers in, 30.6–30.7
untrained sellers and, 30.15–30.16
disposable laboratory supplies, 47.7–47.8
disposal of pharmaceuticals, 44.16, 45.14–45.15
distance learning, 52.6
distribution management
for access to medicines, 1.11
administrative problems in, 22.18
channels in, 6.13–6.14
climatic factors in, 22.14
communications in, 22.15–22.16
cost analysis in, 22.16–22.17
cycle of, 22.4–22.6
delivery schedules in, 22.14
delivery vs. collection systems in, 22.13–22.14
distribution routes in, 22.12, 22.14
features of, 22.7–22.8
glossary terms, 22.18–22.21
goals of, 22.3–22.4
for hospital pharmacies, 45.7–45.8
improving systems in, 22.18
information systems in, 22.15–22.16
kit systems in, 26.3–26.5
of laboratory supplies, 47.11–47.14
logistics managers in, 22.14–22.15
mapping demand in, 22.11
networks for, 22.8–22.9
performance monitoring in, 22.16–22.17
private-sector option in, 22.17–22.18
push and pull systems for, 22.9–22.10
and rational prescribing, 29.11
resources for, 22.14–22.16
resupply intervals in, 22.10–22.11
seasonal variations in, 22.18
staffing levels in, 22.15
storage in, 22.11–22.13
supply entry points in, 22.12
and supply strategies, 8.3–8.4
transport in, 22.13–22.14, 22.18
treatment guidelines and, 17.14
vehicle usage in, 22.14
volume increases in, 22.18
Doha Declaration, 3.5, 3.10
Dominican Republic, 20.6
donations of equipment and supplies, 15.9, 47.16–47.17
donations of pharmaceuticals
experiences with, 15.4–15.5
good practices for, 15.10–15.11
guidelines for, 15.6–15.9
labeling in, 15.8
management of, 15.9
medicine selection in, 15.8
packing in, 15.8
policies for, 15.9–15.11
problems with, 15.2–15.6
in public-private partnerships, 15.11–15.12
quality assurance in, 15.8
shelf life of products, 15.8
donor financing
best practices for, 14.4
bilateral agencies and, 14.5
bilateral donors in, 14.8
challenges in, 14.3–14.5
commodities in, 14.10
consultants in proposals, 14.16–14.17
Debt Relief Initiative and, 14.11
effectiveness of, 14.11–14.13
evaluations in, 14.17
financial assistance via, 14.8–14.10
and financing strategies, 11.12–11.13
Gates Foundation and, 14.20–14.21
government policy on, 14.14
grant resources in, 14.9
health care reforms and, 14.14
impact of projects and, 14.14
multilateral donors in, 14.9
multilateral institutions and, 14.5
NGOs and, 14.5–14.6
performance-based funding in, 14.13
poverty reduction strategy papers in, 14.12–14.13
private foundations in, 14.6, 14.9, 14.15
progress reports in, 14.17
project formulation for, 14.15–14.16
public-private partnerships and, 14.6–14.8
research funds in, 14.10–14.11
sector-wide approach in, 14.11–14.12
securing, 14.13–14.14
sources of, 14.5–14.8
study tours in, 14.10
sustainability of, 14.14
technical expertise in, 14.10
training in, 14.10
types of assistance in, 14.8–14.11
UN agencies in, 14.9
donor-supported global procurement agencies, 18.8
donation forms, 19.4, 44.13
DOTS (directly observed treatment, short course)
for consumer use of medicines, 33.8, 33.11
in Dominican Republic, 20.7
in Nepal, 22.8
in tuberculosis treatment, 26.4
DRAs. See drug regulatory authorities
drug abuse, 45.15
Drug and Therapeutics Bulletin, 29.9, 34.6
drug and therapeutics committees (DTCs)
in Afghanistan, 45.6
in hospital pharmacies, 45.4–45.5
in Kenya, 29.16
for procurement of pharmaceuticals, 18.19
for rational medicine use, 27.12
for rational prescribing, 29.3, 29.10–29.13, 29.16
training programs for, 52.10
drug bulletins, 34.6, 34.12–34.14
drug dumping. See donations of pharmaceuticals
drug monographs, 17.12
drug regulatory authorities (DRAs), 19.3, 19.13–19.14
drug seller franchising, 32.10
drug seller initiatives. See retail drug sellers
drug shop accreditation in Tanzania, 32.6
Drug Shop Provider Association tool kit (MSH), 32.13
drug use restrictions, 45.7
drug use reviews (DURs)
  computer use in, 50.14
  in hospital pharmacies, 45.7
  in rational prescribing, 29.4, 29.11–29.12, 29.14–29.15
  in United States, 29.14–29.15
DTCs. See drug and therapeutics committees
duka la dawa baridi (Tanzania), 32.6–32.7
duration of contracts, 39.15
DURs. See drug use reviews
DVDs, 50.16–50.18

earthquake relief, 26.4
East Timor, 15.4
e-communications, 50.14–50.16
economic characteristics of pharmaceuticals, 9.6–9.10
economic efficiency, 10.9
economic evaluation, 10.11
economic goals, 1.8
economic incentives, 7.7
economic interventions and prescribing, 29.5, 29.17
economic issues and revolving drug funds, 13.7, 13.22
economic markets, 9.3
economic order intervals (EOI), 23.21–23.22
economic order quantity (EOQ), 23.21–23.22
economics for pharmaceutical management
  allocative efficiency in, 10.9–10.10
  annualized capital costs in, 10.13
  average cost per unit in, 10.13
  capital costs in, 10.13
  competition in, 10.5
  concepts of, 10.3–10.4
  cost-benefit analysis in, 10.11, 10.12
  cost-effectiveness analysis in, 10.11–10.14
  cost-minimization analysis in, 10.11
  costs in, 10.10–10.14
  cost-utility analysis in, 10.11, 10.12
  efficiency concepts in, 10.9–10.10
  ethics in, 10.6
  evaluating products in, 10.10–10.14
  externalities in, 10.5
  goals in, 10.4–10.5
  government–private sector interactions on, 10.7–10.9
  incentives in, 10.2, 10.4
  marginal costs in, 10.2, 10.4, 10.13
  market failure in, 10.7
  merit goods in, 10.5
  opportunity costs in, 10.3–10.4
  pharmaco-economic evaluations in, 10.13
  in private sector, 10.5–10.9
  productive efficiency in, 10.9
  in public sector, 10.4–10.5
  rational medicine use and, 27.9–27.10
  recurrent costs in, 10.13
  resource allocation in, 10.3
  scale in, 10.6
  scarcity in, 10.2–10.3
  scope in, 10.6
  sensitivity analysis in, 10.13
  technical efficiency in, 10.9–10.10
  total costs in, 10.13
  variable costs in, 10.13
E-Drug, 50.15
education. See also training programs
  for rational medicine use, 27.9–27.10, 27.12–27.13, 33.19
  for rational prescribing, 29.3–29.10
  of retail drug sellers, 32.3–32.4, 32.11
educational initiatives for medical and pharmacy students
  (survey), 34.7
efficiency
  access to medicines and, 1.13–1.16
  economic, 10.9–10.10
  in financing strategies, 11.13
  national medicine policies and, 4.4
Egypt, 27.4
El Salvador
  access indicators in, 36.11
  medication counseling in, 30.9
  pharmaceutical donations in, 15.4
  tender management in, 21.4
elasticity
  of demand, 9.3–9.4
  of prices, 9.3
  of supply, 9.3
e-learning, 52.7–52.8
Electronic Dispensing Tool (MSH), 49.6
electronic tablet counters, 30.14
emergencies
  health kits for, 15.7
  in inventory management, 23.20
  kit systems for, 26.2–26.3
  quantifying pharmaceutical requirements for, 20.5
  storage facilities and, 42.13
  trays for, 46.12
emergent supply problems diagnosis, 36.3
enablers, 31.15, 33.11
endorsement of medicine policies, 4.14–4.15
EOI. See economic order intervals
EOIs. See expressions of interest
EOQ. See economic order quantity
Epi Info, 50.6
e-procurement, 18.6–18.7
equal misery strategy, 40.12–40.13
equipment
cost of, 22.16
defined, 47.3
for laboratory services, 47.6, 47.15–47.16
management of, 47.16
for medicine information centers, 34.10
starter kits of, 47.9
in storage facilities, 42.17
equity
in financing strategies, 11.13
national medicine policies and, 4.4
in revolving drug funds, 13.12–13.7, 13.22
in supply strategies, 8.5
equity pricing, 9.10
Eritrea, 15.4
erthyromycin, 2.2
Essential Drugs Monitor, 2.4, 2.8
essential medicines
adoption of, 1.10
budget gap analysis for, 11.10
concept of, 1.7–1.8, 2.3–2.6, 16.2–16.4
expenditure trend analysis for, 11.10
financing strategies for, 11.6–11.7
lists of. See essential medicines lists
morbidity and mortality rates and, 1.5
in national medicine policies, 4.7–4.8, 4.14
organizational roles in. See organizational roles
per capita budgets for, 11.10
political visibility and, 11.10
quantification of need for, 11.10
in revolving drug funds. See revolving drug funds
(right to health and, 4.14
selection of, 16.2–16.4
transparency assessment and, 11.10
WHO on, 2.8
essential medicines lists. See also essential medicines
acceptance of, 16.14
context of, 16.6–16.8
defined daily doses in, 40.24
development of, 16.8–16.10
essential medicines concept and, 16.2–16.4
in Ghana, 17.5
implementing and updating, 16.14
in procurement, 18.11–18.13
for rational medicine use, 27.12
for rational prescribing, 29.3
for retail drug sellers, 32.11
revising, 16.12
VEN analysis and, 40.12
by WHO. See WHO Model List of Essential Medicines
Essential Medicines Monitor, 2.4, 2.8
essential supplies and equipment lists, 47.4–47.5, 47.11
estimated-versus fixed-quantity contracts, 21.6–21.7
estimates of pharmaceutical needs, 18.12, 18.15
Estimating Drug Requirements, 20.8, 20.18, 20.23
Estonia, 6.4
ethical guidelines
in investigating medicine use, 28.6
for medicine promotion, 34.8
in the private sector, 10.6
Ethiopia
essential drugs list in, 16.6, 16.10
pharmaceutical management for ART in, 36.4–36.5
security efforts in, 43.12
theft of ARVs in, 43.3
European Pharmacopoeia, 19.4, 19.8
evaluation
in donor financing, 14.17
of economics, 10.11
of interventions, 28.19–28.22
monitoring and. See monitoring and evaluation
of monitoring systems, 48.7
of pharmaceutical products (economic), 10.10–10.14
pharmaco-economic, 10.13
of projects, 38.17–38.18
of suppliers, 21.12–21.13
of tender offers, 21.16
evergreening of medications, 3.6
exceptions to rights conferred (TRIPS Article 30), 3.7
excess stock, 23.18
exchange rates, 39.6, 41.8
exclusive marketing rights (TRIPS Article 70.9), 3.9
exemptions (to user fees and costs), 13.16–13.17
expenditures for pharmaceuticals
ABC analysis in, 40.13–40.19
acquisition price comparisons in, 40.24
acquisitions costs in, 40.5
analyzing costs, tools for, 40.2–40.3
COTs in, 40.21–40.24
deterioration and spoilage costs in, 40.6
equal misery strategy in, 40.12–40.13
expiry costs in, 40.6
expiry dates analysis in, 40.28–40.30
financial opportunity costs in, 40.6
in financing strategies, 11.6–11.10
glossary terms, 40.31
hidden-cost analysis in, 40.30–40.31
inventory-holding costs in, 40.5–40.6, 40.9
inventory pipeline in, 40.7–40.9
lead-time analysis in, 40.26–40.28
loss from inventory in, 40.6
modeling effect of alternatives in, 40.5
obsolescence costs in, 40.6
operating costs in, 40.6
payment-time analysis in, 40.26–40.28
performance indicators in, 40.9
I.12 INDEX

preferential weighting in, 40.12
price comparison analysis in, 40.24–40.26, 40.26
purchasing costs in, 40.6–40.8
revenues vs., 13.14
shortage costs in, 40.8
supply system vs. private-sector prices in, 40.26
supply systems in, 40.5
therapeutic category analysis in, 40.19–40.24
total cost analysis in, 40.3–40.9
transport costs in, 40.6
trend analysis of, 11.10
VEN analysis in, 40.9–40.13
wastage costs in, 40.6
expense ratios, 23.6
expiry costs, 40.6
expiry dates
analysis of, 40.28–40.30
in contracting for pharmaceuticals, 39.9
in health facilities, 46.6
exponential smoothing, 23.21–23.22
exporters, 21.11
expressions of interest, 39.14
externalities
in economics, 10.5
in pricing policies, 9.5
in supply strategies, 8.5
face-to-face contact, 29.9
facility-based health services, 31.7–31.8
facility-level pharmacovigilance, 35.8
facility pharmaceutical budgets, 29.15
FDA. See Food and Drug Administration
feasibility assessments
for contracts, 39.11–39.14
of local pharmaceutical production, 7.8–7.10
in management planning, 38.10
for revolving drug funds, 13.6
of small-scale pharmaceutical production, 45.14
feasibility phase of planning, 42.6–42.8
feedback
in management information systems, 49.7
in monitoring and evaluation, 48.13
for rational prescribing, 29.10–29.11
fees for services, 12.8
FEFO. See first-expiry/first-out
field observation in assessment, 36.17–36.18
field supervision, 48.7
FIFO. See first-in/first-out
financial incentives, 27.13
financial opportunity costs, 40.6
financial planning and management
accounting in, 41.17–41.19
assets in, 41.15
balance sheets in, 41.18–41.19
budgeting in, 41.10–41.12, 41.17
cash planning in, 41.12–41.14
checklist for, 41.15
costing in, 41.9–41.10
computer reports in, 8.17, 50.13
exchange rates in, 41.8
expenditures in, 41.12, 41.15
funding levels in, 41.12
global. See global financing
government systems and, 41.3–41.6
income and expense reports in, 41.17–41.18
inflation in, 41.8
legislation and regulation in, 6.16
long-range, 41.6–41.9
national medicine policies and, 4.7, 4.9
operating budgets in, 41.16
of pharmaceutical programs, 37.10
prices in, 41.8–41.10
in procurement, 18.10–18.12
receipts in, 41.15
reporting in, 41.17–41.19
resources in, 41.12, 41.14–41.17
by retail drug sellers, 32.12
of revolving drug funds, 13.7–13.11, 13.17–13.18
of stock accounts, 41.18
strategies in. See financing strategies
supply strategies and, 8.3–8.4
sustainability in, 1.12, 11.3–11.4, 18.21–18.22
financing health insurance, 12.4–12.5
financing strategies. See also financial planning and
management
access to medicines and, 11.13
administrative requirements in, 11.14
allocative efficiency in, 11.3
budget gap analysis in, 11.10
community prepaid insurance in, 11.11
comparative expenditure analysis in, 11.10
comparison of, 11.13–11.15
controlling demand in, 11.3
development of, 11.14–11.16
development loans in, 11.12–11.13
donor financing in. See donor financing
efficiency in, 11.13
equity in, 11.13
for essential medicines, 11.6–11.7, 11.9–11.10
expenditure trend analysis in, 11.10
foreign aid in, 11.5–11.6
government budgets in, 11.8–11.10
health expenditures in, 11.4–11.7
health insurance in, 11.10–11.12
health services use and, 11.10
high disease burdens and, 11.5
income levels and, 11.4–11.7
increasing resources in, 11.4
insurance coverage in, 11.5, 11.11–11.12
local financing in, 11.12
medical savings accounts in, 11.11
medicine sales in, 11.7–11.8
per capita medicine consumption in, 11.6
per capita pharmaceutical budgets in, 11.10
pharmaceutical expenditures in, 11.6–11.10
political visibility and, 11.10
private health insurance in, 11.11
in private sector, 11.7–11.8
in public sector, 11.8–11.10
quantification of medicine needs in, 11.10
rational medicine use and, 11.13
social health insurance and, 11.11
sustainability in, 11.3–11.4, 11.13
technical efficiency in, 11.3
transparency assessment in, 11.10
user fees in, 11.7–11.8
voluntary financing in, 11.12
fire prevention, 42.13, 44.16, 46.7
first aid, 44.19
first-expiry/first-out (FEFO), 30.3, 46.6
first-in/first-out (FIFO), 30.3
five-year plans, 38.15
fixed-dose combinations (FDCs), 19.18, 26.4
fixed location systems, 44.10
fixed margins, 9.19
fixed medicine allowances, 26.15
flammables, 44.10, 46.6
floor pallets, 44.15–44.16
flow of stock and information, 44.5–44.9
fluid location systems, 44.12
focus group discussions, 28.15–28.16
focused supervision, 37.16
Food and Drug Administration (FDA)
on pharmacovigilance, 35.10
on quality assurance, 19.3
on safety of medicines, 2.10
force field analysis, 37.17–37.18
forecasting requirements. See quantifying pharmaceutical requirements
foreign exchange rates, 13.9
formative research, 29.21–29.22, 32.9
formulary lists, 16.7, 16.10, 18.11–18.13, 29.9
formulary manuals
brand-name drugs in, 17.13
computer production of, 50.11
definition of, 16.7
development of, 17.12–17.13
distribution of, 17.14
drug information in, 17.11
drug monographs in, 17.12
ease of use of, 17.13
for hospitals, 17.13
implementing, 17.14–17.15
information in, 17.10–17.11
lists of, 17.17
in medicine selection, 16.7–16.10
national committees for, 17.12
nonessential medicines in, 17.12–17.13
production of, 17.14
revision of, 17.12
size of, 17.13
treatment guidelines and. See treatment guidelines
formulary systems, 16.7, 45.5–45.7
forwarding agents, 24.3–24.4
framework contracts, 23.15
franchising, 32.7–32.10
fraud control, 43.11–43.12
free trade agreements, 3.14
funding, 18.21–18.22, 34.15. See also financing strategies
fungibility, 14.3
GACPs. See Good Agricultural and Collection Practices
Gantt charts, 38.14–38.16
Gates Foundation, 14.5–14.6, 14.20–14.21
GAVI Alliance, 14.5–14.6
GDF. See Global Drug Facility
GDP. See gross domestic product
generic medicines
history of, 2.4
intellectual property laws and, 3.6
introduction to, 3.3
pricing policies for, 9.8–9.9
procurement of, 18.11
promoting use of, 33.17
selection of, 16.5–16.6
gis location systems (GIS), 50.8
Ghana
access to medicines in, 1.16–1.17, 36.11
CAREshop franchise in, 32.9
education campaign in, 33.19
imprest systems in, 22.12
medication counseling in, 30.9
national medicine policy of, 4.6
small-scale pharmaceutical production in, 45.14
standard treatment guidelines in, 17.5, 29.8
GIS. See geographic information systems
Global Atlas of the Health Workforce, 51.4
Global Drug Facility (GDF), 26.4, 47.8–47.9
global financing. See also donor financing
effectiveness of, 14.11–14.13
Gates Foundation and, 14.20–14.21
private foundations for, 14.15
progress reports in, 14.17
project formulation for, 14.15–14.16
sources of, 14.5–14.8
types of, 14.8–14.11
Global Fund to Fight AIDS, Tuberculosis and Malaria
for access to medicines, 1.14
antiretroviral therapy and, 2.6
financing strategies and, 4.9
human resources crisis and, 51.7
indicators and, 1.11–1.12
laboratory supplies from, 47.11
prequalification of suppliers and, 21.5
quantifying pharmaceutical requirements by, 20.8
Global Initiative on Health Technologies (WHO), 47.3–47.4
global market for pharmaceuticals, 3.2–3.3
global monitoring of quality, 19.8
global positioning systems (GPS), 50.8–50.9
globalization
of intellectual property standards, 3.3–3.10
of legislation and regulation, 6.3–6.6
local production vs., 7.5–7.6
of pharmaceutical industry, 2.10–2.11
pricing policies and, 9.19–9.20
GLPs. See good laboratory practices
GMPs. See good manufacturing practices
Good Agricultural and Collection Practices (GACPs), 5.12
Good Governance for Medicines (WHO)
access to medicines and, 1.10–1.11
codes of conduct by, 51.16
transparency assessments by, 36.12
by WHO, 43.3
good laboratory practices (GLPs), 5.12
good manufacturing practices (GMPs)
legislation and regulation of, 6.8
by local producers, 7.3–7.7
quality assurance in, 19.7–19.8
sterile production in, 45.13
WHO on, 19.13
governance. See Good Governance for Medicines
governments
donor financing and, 14.14
finance systems of, 41.3–41.6
intervention of, 9.17–9.19
medicine policies of. See national medicine policies
private sector and, 10.7–10.9
regulation of medicine use by, 27.13
resource allocation by, 10.3
revolving drug funds and, 13.8–13.9
role in health care of, 8.5–8.7
traditional medicine policies of, 5.8
GPS. See global positioning systems
grants, 14.9, 41.6
gross domestic product (GDP), 11.4, 11.8
Guidelines for Drug Donations, 15.5–15.6
Guinea, 26.8, 31.9
Gujarat state (India), 15.4
HAI. See Health Action International
Haiti, 15.5, 50.14
handheld computers, 50.9
harmonization of regulations, 6.3–6.6, 14.4
Health Action International (HAI)
Drug Prices Project of, 3.17
on essential medicines, 2.4
on essential medicines concept, 2.8
on pricing policies, 9.11–9.15
Health for All Australians, 4.16
health care
contracting for. See contracting for health services
expenditures for, 11.4–11.7
programming, 31.10–31.14
reforms of, 14.14
systems for. See health care systems
use of services for, 11.10
health care systems
credibility of, 19.7
indemnity of, 39.15
rational medicine use and, 27.6–27.7
traditional medicine and, 5.9, 5.12–5.13, 5.15
types of, 5.9
health facility pharmaceutical management. See also
hospital pharmacy management
accountability in, 46.4
adherence of medicines in, 33.9
antibiotic use in, 28.9
arranging stock in, 46.6–46.7
bulk storage in, 46.2, 46.4
checklist for, 46.14–46.15
cleaning in, 46.7
corrosives in, 46.6
discrepancy reports in, 46.10
expiry dates in, 46.6
fire prevention in, 46.7
flammables in, 46.6
home-based care kits in, 46.12
inpatient dispensing in, 46.11–46.12
inventory control in, 46.2–46.3, 46.7–46.9
managing, generally, 46.2–46.3
maximum stock approach in, 46.8
ordering stock in, 46.7–46.9
outpatient dispensing in, 46.11
prepackaging of medicines in, 46.11
receiving stock in, 46.9
record keeping in, 46.7–46.9
refrigeration in, 46.5
rotating stock in, 46.4, 46.6
security in, 46.4, 46.7
in small facilities, 46.9
staff training in, 46.12
stock distribution in, 46.4, 46.9–46.12
storage areas in, 46.3–46.7
stores in, 22.8, 22.14
theft control in, 43.11, 46.5–46.6

health insurance
adverse selection in, 11.11
community prepaid, 11.11
cost escalation in, 11.11
for essential medicines, 11.7
moral hazard in, 11.11
pharmaceutical benefits in. See insurance for pharmaceuticals
private health insurance in, 11.11
rational prescribing and, 29.17
skimming in, 11.11
social, 1.13

health savings accounts. See medical savings accounts (MSAs)

health services. See health care
Healthy Skepticism, 2.8
Heavily Indebted Poor Countries (HIPC), 14.11
herbal medications, 5.5–5.7, 6.13
Herzegovina, 15.4
hidden-cost analysis, 40.30–40.31

high disease burdens, 11.5
HIPC. See Heavily Indebted Poor Countries
historical perspectives
access to medicines in, 2.2–2.3
AIDS, tuberculosis, and malaria in, 2.6–2.7
essential medicines concept in, 2.3–2.6
generic pharmaceuticals in, 2.4
intellectual property laws in, 3.4–3.5
miracle medicines in, 2.2
pharmaceutical industry in, 2.4–2.5
rational medicine use in, 2.5–2.6
UN agencies in, 2.3–2.4
WHO leadership in, 2.3–2.4
HIV/AIDS treatment
antiretrovirals for. See antiretroviral therapy (ART)
community participation in. See community participation
compulsory licensing in, 3.8
cost of, 1.13
diagnostics standards for, 47.6, 47.11
essential medicines lists and, 1.5, 16.4, 16.11
historical perspectives on, 2.6–2.7
human resources crisis in, 51.5
microbicides for, 6.16
pharmacovigilance and, 35.9
prevention of mother-to-child transmission, 36.4
quantifying pharmaceutical requirements for, 20.9
regional collaboration for, 18.10
in Rwanda, 17.15
in Tanzania, 12.12, 36.10, 38.6, 38.13
traditional medicine for, 5.6
vaccines for, 3.18
voluntary licensing in, 3.9
in Zambia, 47.14

holograms, in security management, 19.13
home-based care kits, 46.12
hospital formularies
management of, 45.5–45.7
manuals for, 17.13
rational medicine use and, 27.12
rational prescribing and, 29.3
hospital pharmacy management
after-hours pharmacies in, 45.12
automated dispensing in, 45.9
bulk ward stock systems for, 45.8
controlled substances in, 45.10–45.12
COTs in, 45.12–45.13
dangerous drugs in, 45.10–45.12
disposal of pharmaceuticals in, 45.14–45.15
drug abuse in, 45.15
drug and therapeutics committees in, 45.4–45.7
drug use review in, 45.7
individual medication orders in, 45.8–45.9
inpatient medications in, 45.7–45.12
leakage control in, 45.15
medication distribution systems for, 45.7–45.8
medication treatment records in, 45.9–45.10
medication use in, 45.3
multiple department systems in, 45.5
nonsterile production in, 45.13
organization of services in, 45.4
patient medication profiles in, 45.9
personnel in, 45.4
physical organization in, 45.4
purchasing in, 45.3
repackaging medications in, 45.12–45.13, 45.15
small-scale production in, 45.12–45.14
software for, 50.11
staff responsibilities in, 45.3–45.4
sterile production in, 45.13–45.14
stock management in, 45.3
theft control in, 43.10–43.11
therapeutic substitutions in, 45.6–45.7
unit-dose medicines in, 45.9
ward inspections in, 45.10, 45.12
housekeeping, 44.15–44.17

How to Estimate Warehouse Space for Drugs, 42.7
How to Investigate Drug Use in Health Facilities, 28.7
How to Investigate the Use of Medicines by Consumers, 28.13
How to Use Applied Qualitative Methods to Design Drug Use Interventions, 28.14

human resources management (HRM). See also staffing accountability in, 51.16
assertiveness vs. cooperation in, 51.25–51.26
assessing strength of, 51.9–51.11
avoiding styles in, 51.25–51.26
collaborating styles in, 51.26
communication channels in, 51.21–51.22
competing styles in, 51.25
compromising styles in, 51.26
conducting meetings in, 51.27–51.28
crisis in human resources and, 51.2–51.7
delegation in, 51.26–51.27
disciplining staff in, 51.23–51.25
distribution of staff in, 51.3
fairness in, 51.18–51.19
feedback skills in, 51.21–51.22
job descriptions in, 51.22–51.23
leadership in, 51.11
in medical stores, 44.17
migration of personnel in, 51.3
motivation in, 51.17–51.21
nonverbal communications in, 51.21
norms approach in, 51.15
performance in, 51.15–51.17, 51.20
performance-based financing in, 51.19
preservice training in, 51.3
recruitment in, 51.14–51.15
retention in, 51.17–51.21
role of, 51.7–51.9
staff pressures in, 51.18
staff requirements in, 51.11–51.15
supervisory systems in, 51.17
work priorities in, 51.19
workload approach in, 51.15
human rights, 3.5, 4.14
humidity control, 44.10
hypertension, 28.12
i+Solutions, 52.13
IBRD. See International Bank for Reconstruction and Development
ICB. See international competitive bidding
ICIUM. See International Conferences on Improving Use of Medicines
ICD. See International Classification of Diseases
ICDRA. See International Conference on Drug Regulatory Authorities
ICH. See International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

IDA. See International Development Association;
   International Dispensary Association
IFPMA. See International Federation of Pharmaceutical Manufacturers and Associations
IGPA. See International Generic Pharmaceutical Alliance
impact assessments
   in donor financing, 14.14
evaluation and, 48.8
   indicators in, 14.13
   in pharmaceutical planning, 38.10–38.11
   in pharmaceutical programs, 37.11
   in revolving drug funds, 13.13
importation
   clearing agents in, 24.3–24.4
   controls on, 7.7–7.8
documents for, 24.5–24.8
   forwarding agents in, 24.3–24.4
   insurance claims in, 24.8
   managing, 24.2–24.3
   port clearing in, 24.3–24.8
   units for, 24.4
imprest systems, 22.12
incentives
   in consumer use of medicines, 33.11
   for participation in treatment, 31.15
   payments as, 12.8
   in pharmaco-economics, 10.2, 10.4
   for retail drug sellers, 32.11–32.12
   incremental ordering costs, 23.6
   indemnity insurance, 12.5
   independent demand systems, 23.4
   in-depth interviews, 28.14–28.16
India
   access indicators in, 36.11
   ADR reporting in, 35.15
   medication counseling in, 30.9
   pharmaceutical production in, 7.6
   procurement systems in, 36.7
Indian Ocean tsunami, 15.7, 26.4
indicators
   of access, 36.11
   in management information systems, 49.10–49.11
   of medicine use, 28.7–28.9
   of performance, 36.14–36.15, 39.15, 40.9
   in pharmaceutical management, 36.16–36.17
   pharmaceutical and supply, 48.11–48.12
   of process, 14.13, 48.8
   of reliability, 48.9
   of staffing needs, 51.15
   indigenous knowledge protection, 5.13
   indirect costs, 41.9
Indonesia
   education on medicine use in, 33.19
   essential medicine supply in, 8.17
health facility medicine use in, 28.9
rational prescribing in, 29.13, 29.18
treatment guidelines in, 17.9
tsunami relief in, 15.7, 26.4
industrial feasibility study, 7.9
industry organizations, 2.9
inflation, 41.8
informal distribution channels, 6.13–6.14
informant interviews, 36.17
information
collection of for assessments, 36.15–36.18
in distribution management, 22.15–22.16
failure of, 8.5
for management. See management information systems
on medicines. See medicine information
in program management, 37.10
targets, 36.10, 36.14–36.15
information technology (IT), 33.20, 42.12
infrastructure
for communication with consumers, 33.20
in pharmaceutical production policy, 7.6
for retail drug sellers, 32.11
Initiative on Adherence to Antiretrovirals, of INRUD,
28.10, 33.9
injectable vs. oral antibiotics, 29.13
injection overuse, 27.4
inpatient medications, 45.7–45.12, 46.11–46.12
INRUD. See International Network for the Rational Use
of Drugs
in-service education, 29.7–29.8
inspections
dispensing practices checklist for, 30.11
in distribution cycles, 22.5
legislation and regulation of, 6.8
in medical stores, 44.7, 44.16
of pharmaceutical shipments, 19.15–19.16
Institute for Safe Medication Practices, 35.10
institutional perspectives. See organizational roles
insurance
for health care. See health insurance
for importation, 24.8
for inventory, 24.7
for medicines. See insurance for pharmaceuticals
insurance for pharmaceuticals
access to medicines and, 12.11
adverse selection in, 12.6
appropriate schemes for, 12.17–12.18
budget transfers for, 12.8
capitation payment for, 12.7–12.8
case payments for, 12.8
community based, 12.4, 12.12–12.15
co-payment for, 12.7
cost escalation in, 12.6
cost of medicines in, 12.9–12.11
defining, 12.3
fees for services and, 12.8
financing, 11.5, 12.4–12.5
glossary terms, 12.19–12.20
health or medical savings accounts in, 12.4, 12.16–12.17
incentive payments for, 12.8
market failure in, 12.5
monopolies in, 12.5–12.6
moral hazard in, 12.6
prepayment for, 12.5
private, 12.4, 12.14–12.16
problems with, 12.5–12.6
provider payment mechanisms for, 12.6–12.8
public, 12.3–12.4
purchasing health care services and, 12.5
rational medicine use in, 12.11
reform of, 12.18
revenue collection and, 12.4
risk pooling and, 12.4–12.5
social health insurance and, 12.3–12.4, 12.11–12.12
universal health coverage and, 12.2–12.3
integration
of health care systems, 5.9
of supply chain systems, 18.8
intellectual property law
bilateral trade agreements and, 3.12–3.13
Bolar exception in, 3.7, 3.12
compulsory licensing in, 3.6–3.8, 3.12
constraints to, 3.10–3.14
Doha Declaration on, 3.5, 3.10
exceptions to rights in, 3.7
exclusive marketing rights in, 3.9
free-trade agreements and, 3.14
generic medicines and, 3.6
globalization of, 3.3–3.10
glossary terms, 3.21
history of, 3.4–3.5
international patent laws in, 3.14
issues for policy makers, 3.15
parallel importation in, 3.7, 3.12
patents in, 3.3, 3.6, 3.12, 3.14
pharmaceutical categories and, 3.3
pharmaceutical industry and, 2.10
pharmaceutical market and, 3.2–3.3
R&D for new medicines and, 3.16–3.20
regulation of medicines in, 3.12–3.14
test data protection in, 3.7–3.9, 3.12
on traditional medicine, 5.13–5.14
transitional arrangements and, 3.6
TRIPS and, 3.5–3.6, 3.12–3.13, 3.14
voluntary licensing in, 3.7, 3.9
Intellectual Property Watch, 3.17
Interagency Emergency Health Kit, 15.7, 26.3
**Interagency Guidelines for Establishing a Model Quality Assurance System**, 21.5
Interagency Pharmaceutical Coordination Group, 2.8
interchangeability of medicines, 6.12
Intergovernmental Working Group on Public Health, 3.17
International AIDS Vaccine Initiative, 3.18
International Bank for Reconstruction and Development (IBRD), 14.8
international benchmarking, 9.18
*International Classification of Diseases, 10th Revision*, 28.6
International Classification of Diseases (ICD), 20.19
international competitive bidding (ICB), 21.16
International Conference on Drug Regulatory Authorities (ICDRA), 6.4
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 6.4–6.6, 19.3
International Conference on Primary Health Care, 1.7
International Conferences on Improving Use of Medicines (ICIUM), 1.17, 2.5, 28.20
International Development Association (IDA), 14.8
International Dispensary Association (IDA), 26.12, 40.26
*International Drug Price Indicator Guide*
defined daily doses in, 40.24
for monitoring prices, 9.14
pharmaceutical donations and, 15.10
for price comparison analysis, 40.25–40.26
pricing policies and, 9.12
for procurement, 21.11
quantifying pharmaceutical requirements in, 20.13
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), 2.5, 3.17
international financing. See global financing
International Generic Pharmaceutical Alliance (IGPA), 3.17
International HIV/AIDS Alliance, 2.7, 31.3
International Medical Products Anti-Counterfeiting Taskforce, 19.9
International Network for the Rational Use of Drugs (INRUD)
on dispensing practices, 27.8
historical perspectives on, 2.5
organizational roles of, 2.8–2.9
on rational prescribing, 29.12
International Nonproprietary Names (INNs)
of essential medicines, 16.5
in medicine selection, 16.2
promoting use of, 33.17
in tender lists, 21.14–21.15
International Pharmaceutical Federation (FIP), 51.5–51.7
*International Pharmacopoeia*, 19.4, 19.8
international procurement, 18.7, 21.7–21.8, 21.11
International Red Cross (IRC), 26.3
International Society of Drug Bulletins (ISDB), 2.9, 34.11
international wholesale exporters, 21.11
Internet, 2.10–2.11, 34.3
interrupted time series, 28.21
interventions
in communication with consumers, 33.14–33.18
for medication adherence, 27.9–27
for rational prescribing, 33.12–33.13
See interventions for rational prescribing
interventions for rational prescribing
economic, 29.5, 29.17
educational, 29.3–29.10
focus and target of, 29.5
managerial, 29.5, 29.10–29.17
regulatory, 29.5, 29.17–29.21
strategies for, 29.21–29.22
system oriented, 29.5
targeted, 29.4–29.5
intrauterine devices (IUDs), 20.13
inventory
control of. See inventory control
holding costs, 40.5–40.6, 40.9
managing. See inventory management
pipelines for, 40.7–40.9
shrinkage of, 23.6
taking, 44.9
inventory control. See also inventory management
in distribution cycle, 22.5–22.6
in health facilities, 46.2–46.3, 46.7–46.9
in medical stores, 44.2–44.3
models for, 23.11–23.16
in security management, 43.6, 43.8
inventory management
ABC/FS system in, 23.15
annual purchasing in, 23.12–23.13, 23.15
average consumption in, 23.16
average inventory-holding costs in, 23.6
benefits vs. costs in, 23.8
bin cards in, 23.4
budget status in, 23.18
computer use in, 50.11
confidence in, 23.7
collection-based reordering in, 23.20–23.21
context of, 23.4–23.7
cost in. See inventory control
cyclic counting in, 23.5
demand and supply in, 23.7
dependent demand systems in, 23.4
deviation of consumption in, 23.22–23.23
economic order in, 23.21–23.22
emergency warning levels in, 23.20
excess stock in, 23.18
expense ratios in, 23.6
exponential smoothing in, 23.21–23.22
framework contracts in, 23.15
incremental ordering costs in, 23.6
independent demand systems in, 23.4
inventory shrinkage in, 23.6
"Kardex" systems in, 23.4
for laboratory services, 47.14–47.15
lead times in, 23.16, 23.22–23.23
ledger systems in, 23.4
materials requirements in, 23.4
maximum stock levels in, 23.16–23.17
minimum-maximum stock levels in, 23.19–23.20
minimum orders in, 23.18
modified optional replenishment in, 23.20
net sales to inventory in, 23.6
ordering costs in, 23.7
pack sizes in, 23.18
performance indicators in, 23.6
perpetual purchasing in, 23.14–23.15
procurement period in, 23.17
projecting demands in, 23.17
pull vs. push systems in, 23.4
quantity discounts in, 23.18
reorder frequencies in, 23.11–23.16
reorder levels in, 23.16
reorder quantities in, 23.16–23.19
reordering formulas in, 23.19–23.21
reordering mathematical models in, 23.21–23.23
rising delivery costs in, 23.18
safety stock in, 23.8–23.11, 23.16
scheduled purchasing in, 23.13–23.15
selection of items to stock, 23.7–23.8
service-level stock in, 23.8–23.11
shortage costs in, 23.7
short-dated products in, 23.19
stock position in, 23.17
storage space in, 23.19
theft in, 23.19
transport costs in, 23.7
unit costs in, 23.7
VEn analysis in, 23.7
vertical file cards in, 23.4
wastage in, 23.19
investigating medicine use
aggregation of data in, 28.4, 28.9–28.11
ATC system in, 28.4
case records review in, 28.11–28.12
classifying cases in, 28.6
in communities, 28.13–28.14
comparison groups in, 28.20
consumer interviews in, 28.13
data sources in, 28.4–28.6
defined daily doses in, 28.10–28.11
designing interventions in, 28.10–28.11
ethical issues in, 28.6
evaluating interventions in, 28.19–28.22
focus group discussions in, 28.14–28.16
in-depth interviews in, 28.14–28.16
interrupted time series in, 28.21
measurements in, 28.4–28.7
need for, 28.2–28.4
of oral rehydration solution, 28.6
per capita use in, 28.9–28.10
prescription practices in, 28.10–28.11
in private sector, 28.12–28.13
problems and interventions in, 28.14–28.19
proportion of pharmaceutical budgets in, 28.10
prospective studies in, 28.4
qualitative methods for, 28.14–28.16
quantitative methods for, 28.5, 28.7–28.14
questionnaires in, 28.14–28.16
retrospective studies in, 28.4
sample sizes in, 28.6
scope of data in, 28.4
simulated patient surveys in, 28.14–28.16
standard treatment guidelines in, 28.6
stratification in, 28.6
structured observations in, 28.14–28.16
substitutable product use in, 28.9
surveys in, 28.21
units of analysis in, 28.6
WHO indicators in, 28.7–28.9
invitations to bid, 21.13
IPRsonline.org, 3.17
IRC. See International Red Cross
irrational medicine use. See also rational medicine use
adverse impact of, 27.5–27.6
elements of, 27.3–27.5
factors underlying, 27.6–27.8
ISDB. See International Society of Drug Bulletins
isoniazid, 2.2
IT. See information technology
data aggregation, 42.7
ITNs. See insecticide-treated nets
Java, 48.16
job descriptions, 49.14
Joint Clinical Research Centre (JCRC) (Uganda), 47.3
Joint Medical Stores (JMS) (Uganda), 8.15
"Kardex" systems, 23.4
Kenya
antibiotic use review in, 29.16
antimicrobial resistance in, 40.15
ART programs in, 30.4, 37.17, 48.4–48.5
community health workers in, 32.10
drug seller franchising in, 32.10
education about antimalarials in, 33.16
emergency hiring plans in, 51.16
essential medicines lists in, 16.11–16.12
human resources in, 51.6
kit systems in, 26.5, 26.11
medication counseling in, 33.6
medication treatment records in, 45.10
monitoring medicine fees in, 48.7
rational prescribing in, 29.18
retail drug seller education in, 32.4
traditional medicine in, 5.6
Kenya Forestry Research Institute, 5.6
kit systems
appropriateness of, 26.9, 26.14
contents of, 26.9–26.11
costs of, 26.8–26.9
delivery of, 26.12–26.14
direct requisitions and, 26.13
as distribution strategy, 26.3–26.5
for emergency situations, 26.2–26.3
fixed medicine allowances vs., 26.15
health units receiving, 26.9
implementation of, 26.9–26.14
introduction to, 1.11
for laboratory services, 47.8–47.9
management training for, 26.13
medicines in, 26.9–26.11
modified optional replenishment vs., 26.14
number of kits in, 26.11–26.12
open requisitioning vs., 26.15
ordering within defined limits vs., 26.15
packing of, 26.12
planning flow chart for, 26.10
predefined lists vs., 26.15
procurement for, 26.12
pros and cons of, 26.5–26.8
quality assurance and, 19.18
rational medicine use in, 26.13
record keeping for, 26.12–26.13
stockouts in, 26.13
success conditions for, 26.9
transitioning from, 26.13, 26.14–26.15
waste in, 26.13
Knowledge Ecology International, 3.17
Kuwait, 9.15
Kyrgyzstan, 34.14
labels
in dispensing practices, 30.3–30.7, 30.12–30.13
in pharmaceutical contracts, 39.8
pictograms on, 33.25
laboratory services
budgets for, 47.4
consumables kits in, 47.9
diagnostics selection for, 47.6–47.7
disposable items for, 47.7–47.8
distribution of, 47.11–47.14
donations and, 47.16–47.17
equipment in, 47.9, 47.15–47.16
essential supplies list example, 47.11
health care packages and, 47.4
inventory management for, 47.14–47.15
kits for, 47.8–47.9
management systems for, 47.6–47.15
medical supplies for. See medical supplies
microscope kits in, 47.9
medical supplies
modified optional replenishment vs., 26.14
number of kits in, 26.11–26.12
open requisitioning vs., 26.15
ordering within defined limits vs., 26.15
planning flow chart for, 26.10
predefined lists vs., 26.15
procurement for, 26.12
pros and cons of, 26.5–26.8
quality assurance and, 19.18
rational medicine use in, 26.13
record keeping for, 26.12–26.13
stockouts in, 26.13
success conditions for, 26.9
transitioning from, 26.13, 26.14–26.15
waste in, 26.13
Lans. See local area networks
Lao People's Democratic Republic (P.D.R.)
MTP methodology in, 52.12
national medicine policies in, 4.10
pharmaceutical regulation in, 6.14
rational medicine use in, 27.11
rational prescribing in, 29.18
transparency assessments in, 36.12
Latin American countries
cholera treatment in, 20.6
health facility medicine use in, 28.8
health insurance in, 12.16
price comparison analysis in, 40.25
quantifying pharmaceutical requirements in, 20.13
supply efficiency in, 40.9
TRIPS flexibilities in, 3.11
laws
enforcement of, 43.9
on intellectual property. See intellectual property laws
on pharmaceuticals. See legislation on pharmaceuticals
on revolving drug funds, 13.12
on traditional medicine, 5.15
layout of storage facilities, 42.12–42.13
LDCs. See least developed countries
lead time
analysis, 40.26–40.28
in inventory management, 23.16
for procurement, 20.11
leakage control, 45.15
learning methods, 37.8, 52.6–52.8. See also education
least developed countries (LDCs)
TRIPS and, 3.6, 3.10
Lebanon, 15.5
ledger systems, 23.4
legal reference method of quality assessments, 19.16
legislation on pharmaceuticals. See also regulation of pharmaceuticals
administrative control in, 6.15–6.18
adverse drug reactions and, 6.9
advertising and, 6.10
in the Americas, 6.5
classifying pharmaceuticals in, 6.13
clinical-use information and, 6.10
on counterfeit medicines, 6.14–6.15
on distribution channels, 6.13–6.14
drafting, 6.6–6.7
elements of, 6.7
evolution of, 6.3–6.4
financing and, 6.16
globalization of, 6.3–6.6
guiding principles for, 6.16
harmonization of, 6.3–6.6
on herbal medicines, 6.13
inspections and, 6.8
interchangeability of medicines in, 6.12
key provisions of, 6.7–6.10
licensing of medicines in, 6.8, 6.10–6.13
marketing authorization, 6.10–6.13
medicine promotion and, 6.10
on microbicides for HIV/AIDS, 6.16
need for, 6.2
pharmacopoeias in, 6.6
pharmacovigilance in, 6.8–6.10
production policies and, 7.7
quality of medicines and, 6.10
registration of medicines and, 6.10–6.13
regulations vs. guidelines and, 6.2–6.3
resources required for, 6.15, 6.16
revising, 6.6–6.7
role of, 6.2–6.7
roles of stakeholders in, 6.8
safety of medicines and, 6.10
sanctions in, 6.10
on substandard medicines, 6.14–6.15
supply strategies and, 8.18
on traditional medicines, 6.13
TRIPS and, 6.3–6.4
legislative frameworks, 4.6–4.7
letters of credit (LCs), 24.7, 39.7
Level One Drug Inspectors’ Handbook, 19.11
levels of care, 17.4
licensure requirements
regulation of, 6.8, 6.10–6.13
limited medicines lists, 29.18–29.20
limited procurement lists, 29.11
Lithuania, 15.5
load handling, 44.14–44.15
loading bays, 42.12
local agents, 21.7–21.8
local area networks (LANs), 50.3, 50.7
local importers and distributors, 21.11
local procurement, 18.7
local production. See production policies
“local-to-global” supply chains, 18.8
location of stock within zones, 44.10–44.12
location of survey samples, 9.14
Logframe Handbook, 14.16
LogFrame project planning method, 38.18
logistical framework approach (LFA), 38.18
logistics
definition of, 22.3
in distribution management, 22.14–22.15
for storage facilities, 42.6
long-range financial planning, 41.6–41.9
loss adjustments, 20.11, 40.6
maintenance
in computer use, 50.16–50.18
of equipment, 47.16
of storage facilities, 42.17
of transport vehicles, 25.12–25.13
Makerere University, 51.10, 52.13
malaria treatment. See also Global Fund to Fight AIDS, Tuberculosis and Malaria
ACT for. See artemisinin-based combination therapy (ACT)
community participation in, 31.12
essential medicines for, 1.5
historical perspectives on, 2.6–2.7
quantifying pharmaceutical requirements for, 20.20, 20.22
Malawi, 4.13, 17.14
Malaysia, 9.13, 36.12
Mali, 31.9
management information systems
accuracy in, 49.12
actions based on, 49.17
in Brazil, 49.13
communications in, 49.12
components of, 49.5–49.7
computerizing, 49.11–49.12
data in, 49.4, 49.7, 49.10–49.11, 49.15
definition of, 49.2–49.3
designing, 49.7–49.13
dispensing practices tool for, 49.6
EMP status reports for, 49.20
feedback reports in, 49.7
flow of documents in, 49.8
forms and records for, 49.9
functions of, 49.3–49.4
implementing, 49.13–49.17
importance of, 49.2–49.5
indicators in, 49.11
interpreting information in, 49.16–49.17
in Namibia, 49.11
needs of users in, 49.5
pilot testing of, 49.10
presenting information from, 49.15–49.16
pyramid of, 49.4
record-keeping documents in, 49.7
representativeness vs. comprehensiveness in, 49.10
revising, 49.7–49.13
software for, 49.12
staff in, 49.12–49.13
in tender management, 21.19
management of human resources. See human resources management (HRM)
management of laboratory services, 47.6–47.15
management of medical supplies, 47.6–47.15
management of medicine information centers, 34.11–34.15
management of pharmaceuticals
community participation and, 31.5–31.9
computers in. See computer use
dispensing practices in, 30.10–30.11
distribution in. See distribution management
economics for. See economics for pharmaceutical management
finances in. See financial planning and management
goals for, 1.8
in health facilities. See health facility pharmaceutical management
health services contracts in. See contracting for health services
in hospital pharmacies. See hospital pharmacy management
imprest systems in, 22.12
information for. See management information systems
inventory in. See inventory management
in medical stores. See medical stores management
pharmacovigilance in, 35.7
planning for. See planning for management
procurement in. See procurement of pharmaceuticals
in programs. See program management
in revolving drug funds, 13.17–13.18
security in. See security management
supply strategies in, 8.16–8.18
supply systems assessments in, 36.3–36.5
tender in. See tender management
training programs for. See training programs
transport in. See transport management
waste in, 1.7
management science methods, 38.17–38.18
Management Sciences for Health (MSH)
and access to medicines, 1.16
Drug Shop Initiative tool kit of, 32.13
organizational roles of, 2.9–2.10
pharmaceutical indicators by, 36.16–36.17
price data by, 20.13
Quantimed, 20.9
training programs by, 52.13
manufacturers of pharmaceuticals
contracting with, 39.8
medicine information from, 34.6–34.9
organizations of, 2.5, 3.17
practices of. See good manufacturing practices (GMPs)
in tender management, 21.11
marginal costs and benefits, 10.2, 10.4, 10.13
market
economic, 9.3
failure of economic, 9.4–9.6, 10.7, 12.5
global pharmaceutical, 3.2–3.3
power of economic, 9.6
production policies and, 7.7
supply strategies and, 8.5
marketing of pharmaceuticals, 6.10–6.13, 32.12
MARs. See medication administration records
Martindale: The Extra Pharmacopoeia, 16.13, 28.5
mass media, 33.20
maternal health services, 1.5, 12.7. See also children
maximizing buying power, 9.16
maximum stock levels, 23.16–23.17
MDGs. See Millennium Development Goals
MDRI. See Multilateral Debt Relief Initiative
MDR-TB. See multidrug-resistant tuberculosis
measles treatment, 1.5
mechanical equipment specifications, 42.13
mechanized warehouses, 42.2
Médecins Sans Frontières (MSF), 3.17–3.18, 26.3
media communications, 13.19
medical commodities. See medical supplies
medical devices, defined, 47.3
Medical Letter on Drugs and Therapeutics, 16.13, 29.9, 29.14, 34.6–34.7
medical savings accounts (MSAs), 11.11, 12.4, 12.16–12.17
Medical Stores Department (MSD) (Tanzania), 8.8, 22.11
Medical Stores Limited (MSL) (Zambia), 8.9
medical stores management
alphabetizing stock in, 44.13
career development in, 44.17
classifying stock in, 44.12–44.13
cleaning in, 44.15–44.16, 44.19
cold storage in, 44.10
cold-chain options in, 44.11
commodity codes in, 44.13
delivery vouchers in, 44.24
disposing of stock in, 44.16
dosage forms in, 44.13
FIFO and FEFO in, 44.8
fire precautions in, 44.16
first aid in, 44.19
fixed location systems in, 44.10
flammables in, 44.10
floor pallets in, 44.15
flows in, 44.5–44.9
fluid location systems in, 44.12
housekeeping in, 44.15–44.17
human resources in, 44.17
humidity control in, 44.10
inspections in, 44.10
inventory in, 44.2–44.3, 44.9
load handling in, 44.14–44.15
location of stock in, 44.10–44.12
manual vs. computerized systems in, 44.3
materials management information in, 44.2–44.5
order allocation in, 44.8
order assembly in, 44.8
order delivery in, 44.8–44.9
order picking in, 44.8
organizational chart for, 44.18
packaging specifications in, 44.15
pallet racking in, 44.15
performance monitoring in, 44.2, 44.4–44.5
pest control in, 44.15–44.16
procedures manuals in, 44.17
random bins in, 44.13
receiving reports in, 44.23
register of requisitions in, 44.24
requisition/issue vouchers in, 44.23
rest areas in, 44.19
security in, 44.10, 44.17
semifluid location systems in, 44.12
shelving in, 44.15
space requirements in, 44.7
staff facilities in, 44.17–44.19
stock receipts in, 44.5–44.7
stock records in, 44.4, 44.21–44.24
storing and handling stock in, 44.7, 44.13–44.15
supervising staff in, 44.17
temperature control in, 44.9–44.10
theft control in, 43.10
therapeutic classifications in, 44.12
training staff in, 44.17
warehouse management in, 44.2
zoning stock within stores in, 44.9–44.10
medical supplies
consumables kits, 47.9
cost analysis for, 47.12
disposable items, 47.7–47.8
distribution of, 47.11–47.14
donations and, 47.16–47.17
equipment, 47.9, 47.15–47.17
essential lists of, 47.11
inventory management of, 47.14–47.15
kits of, 47.8–47.9
for laboratory services, 47.7–47.8
management systems for, 47.6–47.15
microscope kits, 47.9
national policies for, 47.4–47.6
procurement of, 47.10
product specifications for, 47.13
quality assurance for, 47.10
quantification of, 47.9–47.10
reusable items, 47.7–47.8
safe disposal of, 47.15
selection of, 47.6–47.7
medication administration records (MARs), 45.9–45.10
medication counseling, 33.6
medication errors, 35.4–35.5, 35.14–35.15
medication order systems, 45.8–45.9
medication order triggers, 35.10–35.11
medication safety terms, 35.6
medication treatment records, 45.9–45.10
medication use. See rational medicine use
medicinal plants protection, 5.13
medicine information
centers for, 34.9–34.11, 34.11–34.15,
Cochrane Collaboration for, 34.5
cost analysis for, 50.15–50.16
computer use, 34.12
drug bulletins for, 34.12
equipment needed for, 34.10
evaluating sources of, 34.3–34.6, 34.12–34.13
funding issues in providing, 34.15
information sources on, 34.17
Internet and, 34.3
library of references on, 34.6
manufacturer provided, 34.6–34.9
proactive outreach for providing, 34.11–34.12
promotion of medicines vs., 34.7–34.9
services providing, 34.10–34.11
setting up centers for, 34.9–34.11
sites for centers for, 34.9–34.10
sources of, 34.14
staff providing, 34.10
type of, 34.2–34.9
medicines sales, 11.7–11.8, 29.17
medicine selection
and access to medicines, 1.10
committees for. See drug and therapeutics committees (DTCs)
criteria for, 16.4–16.5
essential medicines concept in, 16.2–16.4
essential medicines lists in, 16.6–16.14
I.24 INDEX

formulary manuals in, 16.7–16.10  
generic medicines in, 16.5–16.6  
glossary terms, 16.16  
quality assurance in, 19.10–19.11  
for rational prescribing, 29.11  
registered medicines in, 16.7  
in revolving drug funds, 13.17–13.18  
sources of information on, 16.13  
in tender management, 21.10  
therapeutic classifications in, 16.10–16.13  
treatment guidelines in, 16.8–16.10

medicine use  
by consumers. See consumer use of medicines  
data on, 28.4  
investigating. See investigating medicine use  
by prescribers. See rational prescribing  
rational. See rational medicine use  
studies in health facilities, 28.7–28.9  
medicines lists. See essential medicines lists  
medium-term expenditure frameworks (MTEFs), 14.12
MEDLINE database, 50.9
MEDS. See Mission for Essential Drugs and Supplies (Kenya)
MEMS. See Mission for Essential Medical Supplies (Kenya)
minilab assessments, 19.16
microscope kits, 47.9
Millennium Development Goals (MDGs)  
donor financing and, 1.13, 11.3, 14.2  
essential medicines concept in, 2.8  
performance indicators in, 36.14–36.15
MIMS. See Monthly Index of Medical Specialties
Minilab assessments, 19.16
minimum-maximum stock-level formulas, 23.19–23.20
minimum orders, 23.18
Mission for Essential Drugs and Supplies (MEDS) (Kenya), 8.15, 38.8
Mission for Essential Medical Supplies (MEMS) (Tanzania), 8.11
MMT. See methadone maintenance therapy
Model List of Essential Medicines (WHO)  
essential medicines concept in, 2.8  
introduction to, 1.7  
medicine selection and, 16.5–16.13  
national medicine policies and, 4.8  
standard treatment guidelines and, 17.3  
therapeutic category analysis and, 40.21
modified optional replenishment, 23.20, 26.14
Mongolia, 15.10, 27.4
monitoring and evaluation  
budget template for, 48.18  
community participation for, 31.13–31.14  
comparison data in, 48.19  
complexity in, 48.17  
defining, 48.2  
designing, 48.6–48.8  
existing systems and, 48.19  
feedback in, 48.13  
field supervision in, 48.7  
follow-up action from, 48.13–48.15
of health services contracts, 39.14–39.16
indicators for, 48.7–48.12
inputs in, 48.8
measurability in, 48.8
of medicine fees, 48.7
methods in, 48.3–48.6
objectivity in, 48.19
outcomes in, 48.8
outputs in, 48.8
overambitiousness in, 48.17
pitfalls of, 48.17–48.19
in pricing policies, 9.12–9.14, 9.16
processes in, 48.8
in program management, 37.10–37.11
for rational prescribing, 29.10
reliability of indicators in, 48.9
resources required for, 48.17, 48.19
of retail drug sellers, 32.12
of revolving drug funds, 13.19
routine reporting in, 48.3–48.5, 48.7
self-monitoring in, 48.16
sentinel sites in, 48.5–48.6
SMART objectives in, 48.11
special studies in, 48.6–48.7
supervisory visits for, 48.3, 48.8
of suppliers in tender management, 21.13
of supply systems, 36.3
of training programs, 52.16
validity of indicators in, 48.9
monitoring-training-planning (MTP) method, 52.11–52.13
monopolistic competition, 9.4
monopoly, in pharmaceutical market, 9.4
monopoly power, in insurance benefits programs, 12.5–12.6
monopsony, 9.4–9.6, 18.9, 18.12–18.14
Monthly Index of Medical Specialties (MIMS), 34.8
monthly requisitions and deliveries, 22.15
moral hazard, 11.11, 12.6
morbidity method  
for quantifying supplies, 47.9–47.10
Mozambique, 14.12, 15.5
INDEX

MSAs. See medical savings accounts

MSH. See Management Sciences for Health

MTEFs. See medium-term expenditure frameworks

MTP. See monitoring-training-planning method

multidrug-resistant tuberculosis (MDR-TB), 49.13

Multilateral Debt Relief Initiative (MDRI), 14.11

multilateral institutions, 14.5, 14.9

multiple-payer insurance, 12.4

multisectoral planning, 38.6

multisource medicines. See generic medicines

mutual health organizations, 12.12

Namibia

central medical stores in, 44.3

human resources in, 51.4–51.5, 51.12–51.13

management information systems in, 49.11

medicine information center in, 34.11

pharmaceutical management in, 36.5

pharmaceutical regulation in, 6.12

narcotics consumption, 28.11

National Coordinating Council for Medication Error Reporting and Prevention (United States), 35.4

national development goals, 1.8

national essential medicines lists, 16.5–16.11, 16.15

national formulary manuals, 16.7

National Health Insurance Scheme (NHIS) (Ghana), 17.5

National Insurance for Mothers and Children (SNMNN) (Bolivia), 12.7

national medicine policies (NMPs)

access to medicines and, 1.8–1.9, 4.14

accountability and, 4.14

affordability and, 4.7, 4.9

in Australia, 4.16

components of, 4.5–4.9

constraints to, 4.18

corruption and, 4.18

definition of, 4.3–4.5

drafting of, 4.13

endorsement of, 4.14–4.15

essential medicines in, 4.8, 4.14

evaluating, 4.7, 4.17–4.18

facilitating factors for, 4.18

financial strategies for, 4.7, 4.9

flexibility in, 4.15

formulation of, 4.12–4.15

goals of, 4.4

goals and objectives in, 4.13

human resources and, 4.7, 4.9

human rights and, 4.14

implementing, 4.15–4.17

in Lao PDR, 4.10

launching, 4.15

legislative and regulatory framework for, 4.6–4.7

macroeconomics and, 4.18

of Malawi, 4.13

monitoring, 4.7, 4.17–4.18

opposition to, 4.18

political will and, 4.18

priorities in, 4.9–4.12

rational medicine use and, 4.7, 4.9, 27.12

rational prescribing and, 29.3

research and, 4.7

resources and, 4.18

stakeholders in, 4.5–4.6

structure of, 4.3, 4.11

supply strategies and, 4.7–4.8

support for, 4.15, 4.18

technical cooperation in, 4.7

technical expertise and, 4.18

transparency and, 4.14

values and, 4.18

in Yemen, 4.17

national-level pharmacovigilance, 35.8–35.9

national medicines committees (NMCs), 40.12

national policies for laboratory services, 47.4–47.6

national policies for medical supplies, 47.4–47.6

needs assessments

in program management, 37.16

for storage facilities, 42.4

in training programs, 52.4

neglected diseases, 3.16–3.18

neighbor-to-neighbor education, 33.16

Nepal

community case management in, 31.7

distribution challenges in, 22.8

education on medicine use in, 33.19

rational prescribing in, 29.19

The Netherlands, 6.4

The New Emergency Health Kit, 15.6

New Zealand, 9.5

NGOs. See nongovernmental organizations

Nicaragua, 17.5, 34.14

Nigeria, 1.17, 28.12, 32.4

NIH Consensus Development Conference Statement on the Management of Hepatitis B, 34.6

NMPs. See national medicine policies

noncompliance penalties in contracts, 39.15

nonessential medicines, 17.12–17.13, 40.10

nonformulary medicines, 45.8

nongovernmental organizations (NGOs)

for access to medicines, 1.11, 1.17

assessing supply systems of, 36.11–36.15

donor financing and, 14.5–14.7, 14.15–14.18

esential medicines services of, 2.8, 8.15

expenditures of, 40.27

importation by, 24.8

not-for-profit services of, 8.14–8.15

price comparison analysis in, 40.27
I.26 INDEX

procurement by, 18.6–18.9
and supply systems, 8.8, 8.11, 8.13
transport fleets of, 25.8, 25.12
nonprofit procurement agencies, 18.8–18.9
nonsterile production of pharmaceuticals, 45.13
Nordic ATC system, 16.10
Norway, 2.3
not-for-profit pharmaceutical services, 8.14–8.15
nystatin, 2.2

obsolescence costs, 40.6
OECD. See Organisation for Economic Co-operation and Development
OECS/PPS. See Organisation of Eastern Caribbean States Pharmaceutical Procurement Service
oligopolistic competition, 9.4
open requisitioning, 26.15
open tender
managing, 21.15
for procurement, 18.6
restricted tender vs., 21.4
storage facilities and, 42.15
operating budgets, 41.10, 41.16
operating costs, 13.8, 40.6
operational plans, 38.10–38.11
opinion leaders for prescribing practices, 29.10
opinion surveys, 13.19
opportunity costs, 10.2–10.4
options analysis, 36.4, 38.9–38.10
oral rehydration solution (ORS) or therapy (ORT), 20.6, 27.4–27.5, 28.6, 31.12
oral vs. injectable antibiotics, 29.13
orders of medicines and supplies
allocating, 44.8
assembling, 44.8
cost of, 23.7
defined limits for, 26.15
dispatch and delivery of, 44.8–44.9
picking, 44.12
quantities in, 43.11
reports on, 50.13
value calculations of, 42.7
Organisation for Economic Co-operation and Development (OECD), 7.8
organizational charts, 44.18
organizational roles
of advocacy groups, 2.7
of community-based organizations, 2.7
intellectual property laws and, 2.10
of NGOs, 2.8–2.9
of pharmaceutical industry, 2.9–2.11
of regulatory bodies, 2.9
of UN agencies, 2.8
original brands, 3.3
ORS. See oral rehydration solution
ORT. See oral rehydration therapy
outpatient departments, 43.11
outpatient dispensing, 46.11
pack sizes, 23.18
packaging
for dispensing, 30.11–30.12
materials for, 30.8
in pharmaceutical contracts and tenders, 39.8–39.9
specifications for, 44.15
of supply kits, 26.12
packing lists, 24.7
Pakistan, 27.4
pallet racking, 42.13, 44.15
Pan American Health Organization (PAHO), 6.5, 18.9, 18.14
Pan American Network for Drug Regulatory Harmonization (PANDRH), 6.5
pan weighing scales, 30.14
Papua New Guinea
kit system in, 26.6
pharmaceutical contracting in, 39.13
pharmaceutical tender in, 21.14
parallel health care systems, 5.9
parallel importation, 3.7, 3.12
participatory mapping, 31.11
Partnership for Maternal, Newborn & Child Health, 14.7
passive data collection, 35.10
patents
in bilateral trade agreements, 3.12
history of, 2.4
intellectual property laws, 3.6
in pharmaceutical contracts, 39.10
in pharmaceutical sector, 3.3
in pricing policies, 9.8
R&D for new medicines and, 3.16
patients
counseling for, 30.8–30.10
diagnosis of, 29.10, 33.3–33.6
kits for, 26.4
medication profiles of, 45.9
rational medicine use by, 27.8
revolving drug funds and, 13.14, 13.18–13.19
treatment guidelines for, 17.3, 17.6
payments
currency for, 39.6–39.7
reliable mechanisms for, 18.9–18.12, 18.22
terms for, 39.7, 39.15
payment-time analysis, 40.26, 40.28
PDAs. See personal digital assistants
pedigrees of products, 19.13
penicillin, 1.3, 2.2
PEPFAR. See U.S. President's Emergency Plan for AIDS Relief
per capita health expenditures, 1.6
per capita medicine consumption, 11.6, 28.9–28.10
per capita pharmaceutical budgets, 11.10
performance
in assessing supply systems, 36.5, 36.14–36.15
in distribution management, 22.16–22.17
funding based on, 14.13
in health services contracts, 39.14–39.15
in inventory management, 23.6
in medical stores, 44.2, 44.4–44.5
in pharmaceutical contracts, 39.9–39.10
in program management, 37.2–37.3
targets for, 48.10–48.11
periodic-order contracts, 21.6–21.7
perpetual purchasing, 23.14–23.15
personal digital assistants (PDAs), 17.14, 50.3, 50.9
personnel. See human resources management (HRM)
PERT. See project evaluation and review technique
perverse financial incentives, 29.4
pest control, 44.15–44.16
Pharmaceutical Benefits Schedule (PBS) (Australia), 10.8
pharmaceutical companies. See pharmaceutical industry
Pharmaceutical Health and Rational Use of Medicines (PHARM), 4.16
pharmaceutical industry
changes in, 2.9–2.11
globalization and, 2.10–2.11
historical perspectives on, 2.4–2.5
intellectual property laws and, 2.10
Internet and, 2.10–2.11
national medicine policies and. See national medicine policies (nMPs)
organizational roles in, 2.9–2.11
patents and, 3.3
pricing policies in, 9.10
public-private initiatives and, 2.10
Pharmaceutical Procurement Service (PPS) (Eastern Caribbean), 23.14
Pharmaceutical Research and Manufacturers of America (PhRMA), 3.17
pharmaceuticals
assessing supply systems for. See supply systems assessment
distribution of. See distribution management expenditures for. See expenditures for pharmaceuticals financing for. See financing strategies indicator (tracer), 48.11–48.12
insurance benefits for. See insurance for pharmaceuticals legislation on. See legislation on pharmaceuticals management of. See management of pharmaceuticals manufacturers of. See manufacturers of pharmaceuticals pricing policies for. See pricing policies procurement contracts for. See contracting for pharmaceuticals product registration for, 50.14
production policies for. See production policies programs for. See program management quality assurance for. See quality assurance for pharmaceuticals registration of, 29.17–29.18
requirements for. See quantifying pharmaceutical requirements supply kits for. See kit systems supply management for. See supply management supply strategies for. See supply strategies tender for. See tender management
pharmacies in hospitals. See hospital pharmacy management
pharmacists, 27.13, 37.4
pharmacaco-economic analysis, 9.16, 10.8, 10.13–10.14
Pharmacologic-Therapeutic Classification, 40.21
pharmacology education, 29.6–29.7
pharmacopoeias, 6.6
pharmacovigilance
ADE/product quality problem form, 35.13
ADR reporting in, 35.15
adverse drug events and, 35.3, 35.5–35.6
adverse drug reactions and, 35.3–35.4, 35.6
data collection and use in, 35.10–35.15
definition of, 35.2–35.3
designing systems for, 35.6–35.10
at facility level, 35.8
framework for, 35.8
at international level, 35.10
medication errors and, 35.4–35.5, 35.14–35.15
at national level, 35.8–35.9
in public health programs, 35.9–35.10
regulation for, 6.8–6.10
roles of partners in, 35.9
safe medication practices, 35.16
in traditional medicine, 5.12
trigger detection methods in, 35.11
pharmacy benefit programs, 39.3
Pharmacy Education Taskforce Action Plan 2008–10, 51.7
pharmacy personnel
dispensing practices of, 30.14–30.16
human resources crisis and, 51.4–51.7
pharmacists, 27.13, 37.4
PharmWeb, 50.15
Philippines, 9.15, 36.12
Physicians’ Desk Reference, 34.8
pictograms, 33.8–33.9, 33.25
pilot testing, 13.13, 49.10
pipeline calculations, 13.10
planning for management
activity-time charts in, 38.14
assessments in, 38.7–38.9
for community participation, 31.13
components of, 38.13
crises and, 38.7
criteria for, 38.10
failure of, 38.19–38.21
feasibility assessment for, 38.10
five-year plans in, 38.15
framework of, 38.7–38.8
goals of, 38.4, 38.9
LogFrame projects in, 38.18
management science in, 38.17–38.18
multisectoral teams for, 38.6
objectives of, 38.4–38.5
operational plans in, 38.10–38.11
options analysis in, 38.9–38.10
process of, 38.2–38.6
of programs, 37.8–37.11, 38.2–38.6, 38.11–38.14
progress checks in, 38.17
progress review cycles in, 38.19
for rational medicine use, 38.12
of revolving drug funds, 13.6
software for, 38.18–38.19
of storage facilities. See storage facilities
strategic, 38.2–38.3, 38.6–38.11
of supply systems assessments, 36.18–36.19
teams for, 38.5–38.6
three-year plans in, 38.16
top-down vs. bottom-up, 38.5
PMTCT. See prevention of mother-to-child transmission
pneumonia treatment, 31.8
PolicyMaker, 36.14
political mapping, 36.14
polypharmacy, 27.3
pooled procurement, 18.8–18.9, 18.14
poor-quality pharmaceuticals, 19.7–19.8
port clearing. See also importation
contracting for, 24.3
in distribution cycle, 22.5
documents for, 24.5, 24.7
expediting, 24.5–24.8
overview of, 24.5
theft control in, 43.10
postqualification of suppliers, 21.4
poverty reduction strategy papers, 14.12–14.13
PPS. See Pharmaceutical Procurement Service (Eastern Caribbean)
predictive accuracy, 20.4
prefabricated buildings, 42.4, 42.8–42.9, 42.14–42.15
preferential weighting, 40.12
prepackaging of medicines. See also kit systems
in consumer use of medicines, 33.10
in dispensing practices, 30.13–30.14
in health facilities, 46.11
prequalification of medicines, 19.12
prequalification of suppliers
by Global Fund to Fight AIDS, Tuberculosis and Malaria, 21.5
by UNICEF, 21.5
prequalification tendering, 42.15
prescribers, 27.7–27.8, 27.12
prescribing rationally. See rational prescribing
prescription fees, 13.14
prescription patterns. See dispensing practices
Prescrire International, 34.6
presentations
computer use for, 50.6
on supply systems assessments, 36.19
in training programs, 52.15
preservice education, 29.6–29.7
prevention of mother-to-child transmission (PMTCT), 20.9, 36.4–36.5
preventive health care, 31.5
price comparison analysis, 9.12–9.14, 40.24–40.27
prices
controlling, 9.18
dispensed selling, 9.11–9.12
landed, 9.11
levels of, 41.8
per unit, 18.3–18.5
policies for. See pricing policies
private-sector vs. public supply system, 40.26
and rational prescribing, 29.15
retail, 9.11
in revolving drug funds, 13.13–13.17
setting of, 29.17, 41.9–41.10
subsidies for, 13.9
theory for determining, 9.2–9.3
wholesale, 9.11
price/volume agreements, 9.17
pricing policies
assessing, 9.15–9.16
brand premiums in, 9.18
branded off-patent medicines in, 9.9–9.10
buyer strategies in, 9.14–9.17
buying power in, 9.16
capitation systems in, 9.19
demand and supply in, 9.2–9.3
digressive markups in, 9.19
elasticity in, 9.3–9.4
fixed margins in, 9.19
for generic medicines, 9.8–9.9
globalization and, 9.19–9.20
government intervention and, 9.17–9.19
international benchmarking in, 9.18
markets and, 9.3–9.6
monitoring prices in, 9.12–9.14, 9.16
negotiating prices in, 9.16
package agreements in, 9.16–9.17
for patented medicines, 9.8
pharmaceutical companies and, 9.10
pharmaco-economic analysis in, 9.16
price comparisons and, 9.12–9.14
price controls in, 9.18
price/volume agreements in, 9.17
profit controls in, 9.18
rebates in, 9.17
reference pricing in, 9.18
supply chain factors in, 9.10–9.13
survey samples in, 9.14
tariffs and taxes in, 9.18–9.19
tendering and, 9.16
theory of price determination in, 9.2–9.3
variable pricing in, 9.10–9.12
WHO/HAI method in price monitoring, 9.14–9.15
primary contracts, 21.7
primary distributor systems, 8.11–8.12, 18.17
primary health kits, 22.11, 26.13
primary production of pharmaceuticals, 7.3
primary suppliers of pharmaceuticals, 21.11
prime vendor supply systems, 8.11
private foundations, 14.6, 14.9, 14.15
private health insurance, 11.11, 12.4, 12.14–12.16
private sector
  distribution of medicines and supplies in, 22.4, 22.17–22.18
economics in, 10.5–10.9
financing strategies in, 11.7–11.8
health services contracts in, 39.13–39.14
medicine use in, 28.12–28.13
prices in, 40.26
public sector and. See public-private partnerships
suppliers in, 8.3, 18.17
supply systems in, 8.12, 8.18, 36.12–36.13
pro forma invoices, 24.7
problems with medicine use
  analyzing, 33.14
  identifying, 33.12–33.13
  interventions in, 28.14–28.20
  prioritizing, 33.13
procurement cost estimates, 20.13
procurement information systems, 21.19–21.24, 44.3–44.4
procurement of pharmaceuticals
  ABC analysis in, 18.15
  acquisitions costs in, 40.5
  aggregating demand in, 18.13
  annual audit of, 18.12, 18.16
 assessment of, 18.11, 36.7
 autonomous supply agencies in, 18.16
central medical stores in, 18.16
committees for, 18.19
competitive, 18.7, 18.12, 18.14
computers and, 50.11
coordinated informed buying in, 18.11
costs in, 18.3–18.6
currency exchange in, 18.22
cycle of, 18.3–18.4
direct delivery systems and, 18.16
in distribution cycle, 22.5
esential medicines or formulary lists and, 18.11–18.13
estimates of need in, 18.12, 18.15
financial management in, 18.10–18.12
financial sustainability in, 18.21–18.22
funding sources for, 18.21–18.22
generic medicines in, 18.11
global agencies for, 18.8
glossary of terms, 18.22–18.26
good practices for, 18.10–18.16
Internet and, 18.6–18.7
for kit systems, 26.12
“local-to-global” supply chains in, 18.8
manuals for, 18.20–18.21
market information and, 18.19–18.20
medicine selection committees in, 18.19
methods for, 18.6–18.10
monopsony commitment in, 18.9, 18.12, 18.14
nonprofit agencies for, 18.8–18.9
open tender in, 18.6
payment mechanisms in, 18.9–18.12, 18.22
percentage fees in, 18.9
periods for, 20.11, 23.17
pooled, 18.8–18.9, 18.14
prices in, 18.3–18.6
primary distributor systems in, 18.17
private suppliers in, 18.17
quality assurance in, 18.12, 18.16
quantification for, 20.4–20.5
rational prescribing in, 29.11
regional collaboration in, 18.10–18.11
reorder frequencies in, 18.5
reporting on, 18.12, 18.16, 21.21–21.23
responsibilities in, 18.18–18.19
restricted tender in, 18.6
reverse auction in, 18.6–18.7
in revolving drug funds, 13.18
staffing requirements in, 18.19
supervision of, 18.18
suppliers in, 18.12–18.14
technical assistance for, 18.20–18.21
tender management in, 18.19, 21.3
therapeutic category analysis in, 18.15
tracking performance in, 18.20
transparency in, 18.12, 18.15
unit prices in, 18.3–18.5
VEN analysis in, 18.15
visible vs. hidden costs in, 18.5–18.6
volume in, 18.12–18.13
written procedures for, 18.12, 18.15
procurement and supply management, 18.20, 36.2–36.3, 47.11
product identification technology, 19.15
product master files, 50.22–50.24
product problem reporting systems, 19.18–19.20
production policies
duties and import controls in, 7.7–7.8
economic incentives in, 7.7
globalization and, 7.5–7.6
infrastructure in, 7.6
local production and, 7.3–7.10
market factors in, 7.7
for primary production, 7.3
public-private partnerships in, 7.8
public sector in, 7.10
regulatory and legal provisions in, 7.7
on role of producers, 2.9–2.11
for secondary production, 7.3
for tertiary production, 7.3
productive efficiency, 10.9
profit controls, 9.18
program management
best practices in, 37.6–37.11
change management in, 37.15–37.20
crisis management in, 37.5
cycle of, 37.8–37.11
decision making in, 37.12–37.13
focused supervision in, 37.16
force field analysis in, 37.17–37.18
glossary of terms, 37.21
interactive system design in, 37.16
leadership in, 37.2–37.8
managers in, 37.3–37.8
monitoring and evaluation in, 37.10–37.11
needs assessment in, 37.16
negotiating in, 37.14–37.15
operations supervision in, 37.5
for performance, 37.2–37.3
phased implementation in, 37.16–37.17
planning phase of, 37.8–37.10, 38.2–38.3, 38.11–38.14
priority setting in, 37.11–37.12
problem solving in, 37.12–37.13
skills in, 37.6, 37.11–37.15
time management in, 37.12
traditional vs. modern approaches to, 37.5
Programme for International Drug Monitoring (WHO), 35.10
progress reviews
cycle of, 38.19
in donor financing, 14.17
for management planning, 38.17
for rational medicine use, 48.14
project briefs, 42.10–42.11
project evaluation and review technique (PERT), 38.17–38.18
project planning, 38.17–38.19
projecting demand, 23.17–23.18
promotion of medicines, 6.10, 34.7–34.9
prospective studies, for investigating medicine use, 28.4
provider-patient communications, 33.4–33.6
provider payment mechanisms, 12.6–12.8
public health services. See also public sector
access to medicines via, 1.3, 1.7–1.8
expenditure goals for, 10.4
insurance, 12.3–12.4
pharmacovigilance in, 35.9–35.10
R&D for new medicines in, 3.18
public-private partnerships
donor financing and, 14.6–14.8
initiatives for, 2.10
and production policy, 7.8
for R&D for new medicines, 3.18
for storage facilities, 42.5, 42.15
public sector. See also public health services
in distribution management, 22.4
economics in, 10.4–10.5
financing strategies in, 11.8–11.10
private-sector and. See public-private partnerships
production of pharmaceuticals in, 7.10
spending in, 11.4–11.5
supply systems and, 8.11
PubMed, 50.15
pull distribution systems, 22.10
pull vs. push inventory systems, 23.4
push distribution systems, 22.9–22.10
QALY. See quality-adjusted life-year
qualitative data, 36.14, 36.18
qualitative research methods, 28.14–28.16
quality assurance
in access to medicines, 1.8
for health care services, 27.5
for laboratory services, 47.10
for medical supplies, 47.10
in procurement, 18.12, 18.16
records in, 21.20
quality-adjusted life-year (QALY), 10.12
quantification of laboratory and medical supplies, 47.9–47.10
quantifying pharmaceutical requirements
  action plans for, 20.6–20.8
  actual consumption vs. theoretical need in, 20.5
  adjusting final quantities in, 20.13–20.15
  applications of, 20.4–20.5
  centralized vs. decentralized approaches to, 20.8–20.9
  changes impacting, 20.11
  computers and, 20.9–20.10, 50.9–50.11
  consumption method for, 20.3–20.5, 20.15–20.18
  cross-checking results of, 20.11–20.13
  lead time effects in, 20.11
  loss adjustments, 20.11
  medicines lists in, 20.10
  predictive accuracy in, 20.4
  reconciling final quantities in, 20.13–20.15
  safety stock in, 20.11
  service-level projections in, 20.4–20.5, 20.26–20.28
  supply pipeline in, 20.10
  for tenders, 21.10
  time estimates for, 20.10
Quantimed, 20.9, 50.11
quantitative data, 36.14
quantitative research methods, 28.5, 28.7–28.14
questionnaires, use in research, 28.14–28.16

R&D for new medicines
  alternative paradigms for, 3.19–3.20
  in developing countries, 3.19–3.20
  intellectual property law and, 3.16–3.20
  for neglected diseases, 3.16–3.18
  public-private partnerships for, 3.18
  technology transfer in, 3.18–3.19
  trends in, 3.16
radio frequency identification (RFID), 19.13, 19.15
randomized clinical trials, 34.5
Rapid Pharmaceutical Management Assessment, 36.18
ration kit systems, 26.2, 26.16. See also kit systems
rational medicine use
  access to medicines and, 1.11–1.12
  antimicrobial resistance and, 27.5–27.6, 27.11, 27.14
  community participation and, 27.8, 31.8–31.9
  by consumers. See consumer use of medicines
costs and, 27.6
  defining, 27.2–27.3
dispensers and, 27.7–27.8
drug and therapeutics committees for, 27.12
education for, 27.12–27.13
essential medicines lists for, 27.12
financial strategies for, 11.13, 27.13
glossary of terms, 27.14–27.15
- governments and, 27.13
- health systems impacting, 27.6–27.7
- historical perspectives on, 2.5–2.6
- hospital formularies for, 27.12
- information sources on, 27.14
- insurance and, 12.11
- interventions for, 27.10–27.14
- irrational use vs., 27.3–27.8
- injection overuse vs., 27.4
- in kit systems, 26.13
- licensure requirements and, 27.12
- national medicine policies and, 4.7, 4.9, 27.11
- national multidisciplinary bodies for, 27.12
- pharmacists and, 27.13
- planning for, 38.12
- polypharmacy vs., 27.3
- prescribing for. See rational prescribing
- professional associations for, 27.12
- in revolving drug funds, 13.18
- social marketing for, 33.14
- standard treatment guidelines for, 27.12
- strategies for, 27.9–27.14
- and traditional medicine, 5.8, 5.14–5.16
- underuse of effective medicines vs., 27.5
- unsafe medicines vs., 27.4–27.5
- wrong medicines vs., 27.4
- rational prescribing
  - of antibiotics, 29.16
  - benchmarks for, 29.11
  - capitation-based reimbursement and, 29.17
  - clinical newsletters for, 29.9
  - conceptual framework for, 29.2–29.4
  - consumer organizations for, 29.4
  - core strategies for, 29.3–29.4
  - cost bar graphs for, 29.15
  - cost information in, 29.13–29.14
  - COTIs in, 29.17
  - data for, 29.11–29.12
  - defined daily doses in, 29.4
  - dispensing practices and, 29.15, 29.20–29.21
  - drug and therapeutics committees for, 29.3, 29.10–29.13, 29.16
  - drug use reviews in, 29.4, 29.11–29.12, 29.14–29.15
  - economic interventions for, 29.5, 29.17
  - educational interventions for, 29.3–29.10
  - essential medicines lists and, 29.3
  - face-to-face contact and, 29.9
  - facility budgets and, 29.15
  - feedback for, 29.10–29.11
  - formative vs. intervention studies in, 29.21–29.22
  - group educational activities for, 29.8–29.9
  - hospital formularies and, 29.3
  - illustrated materials for, 29.9
- in-service education for, 29.7–29.8
- insurance and, 12.10, 29.17
- interventions for, generally, 29.4–29.5, 29.21–29.22
- licensure requirements and, 29.3
- limited medicines lists and, 29.18–29.20
- limited procurement lists for, 29.11
- managerial interventions for, 29.5, 29.10–29.17
- medicine formularies for, 29.9
- medicine use and. See rational medicine use
- monitoring, 29.10
- national medicine policies and, 29.3
- opinion leaders and, 29.10
- patient charts and, 29.11
- patient education and, 29.10
- perverse financial incentives vs., 29.4
- preservice education, 29.6–29.7
- prices and, 29.15, 29.17
- printed materials for, 29.9
- registration of pharmaceuticals and, 29.17–29.21
- regulations for, 29.3–29.5, 29.17–29.21
- restrictions in, 29.20
- selection of medicines in, 29.11
- social marketing for, 29.22
- standard treatment guidelines and, 29.3, 29.8, 29.15
- supervision for, 29.8, 29.10
- system-oriented interventions for, 29.5
- targeted interventions for, 29.4–29.5
- training for, 29.3–29.7
- RDFs. See revolving drug funds
- rebates, 9.17
- rebids, 21.7
- recalling products, 19.20
- receiving
  - bays, 46.3
  - reports on, 44.23
- shipments, 22.5
- RECOMBIVAX HB (hepatitis B vaccine, recombinant), 35.4
- record keeping
  - in dispensing practices, 30.7
  - documents for, 49.7
  - in health facilities, 46.7–46.9
  - for kit systems, 26.12–26.13
  - by retail drug sellers, 32.11
  - in tender management, 21.19–21.23
- recurrent costs, 10.13
- reference manuals. See formulary manuals
- reference pricing, 9.18
- refrigeration, 46.5
- Regional Technical Resource Collaboration (RTRC), 52.13
- register of requisitions, 44.24
- registration of pharmaceuticals
  - essential medicines lists and, 16.7
in importation, 24.7
legislation on, 6.10–6.13
regulation of pharmaceuticals. See also legislation on pharmaceuticals
access to medicines and, 1.18
definition of, 10.7
national medicine policies and, 4.6–4.7
production policies and, 7.7
for rational medicine use, 27.9–27.10
for rational prescribing, 29.3–29.5, 29.17–29.21
traditional medicine in, 5.8, 5.10–5.11, 5.15
regulation of retail drug sellers, 32.4–32.5, 32.11
regulation of storage facilities, 42.8
reimbursement insurance systems, 12.5
reordering
formulas for, 23.19–23.21
frequency in, 18.5, 23.11–23.16
levels, 23.16
mathematical models for, 23.21–23.23
quantities in, 23.16–23.19
repackaging medications, 45.12–45.15, 45.15
reporting
in financial management, 41.17–41.19
in health services contracts, 39.15
on procurement of pharmaceuticals, 18.12, 18.16
on supply systems, 36.19
requirements for pharmaceuticals. See quantifying pharmaceutical requirements
requisitions, 22.5–22.6, 44.23
research
donor financing of, 14.10–14.11
human resources development and, 4.9
in national medicine policies, 4.7
in tender management, 21.11
on traditional medicine, 5.15
research and development of new medicines. See R&D for new medicines
resources
control of, 41.14–41.17
in distribution management, 22.14–22.16
government allocation of, 10.3
human. See human resources management (HRM)
for monitoring and evaluation, 48.17, 48.19
national medicine policies and, 4.18
regulatory authorities and, 6.15
respiratory infections, 1.5
restricted tender, 18.6, 21.4–21.5
restrictions on prescribing, 29.20
resupply intervals, 22.10–22.11
retail drug sellers
accreditation and, 32.6–32.9
best practices for, 32.5–32.7
business ethics and, 32.12
in developing countries, generally, 32.2–32.3
education of, 32.3–32.4, 32.11
essential medicines lists and, 32.11
financial management by, 32.12
formative research for, 32.9–32.11
franchising and, 32.7–32.10
improving practices of, 32.9–32.13
incentives for, 32.11–32.12
infrastructure of, 32.11
marketing and communications for, 32.12
monitoring and supervision of, 32.12
popularity of as source of health care, 32.2–32.3
problems with, 32.3
quality assurance and, 32.11–32.13
record keeping by, 32.11
regulation of, 32.4–32.5, 32.11
social marketing and, 32.5
staff qualifications, 32.11
stakeholder engagement in, 32.5, 32.11–32.12, 32.14
strengthening role of, 32.3–32.5
in supply strategies, 8.15–8.16
tool kit for, 32.13
retail prices, 9.11
retrospective studies, 28.4, 36.17
reusable medical supplies, 47.7–47.8
revenue collection, 12.4, 13.8
reverse auctions, 18.6–18.7
revolving drug funds (RDFs)
administration of, 13.7, 13.13
balance sheets for, 41.19
bottom-up vs. top-down implementation of, 13.12
capitalization requirements for, 13.9–13.13
cash planning in, 41.12–41.14
community involvement in, 13.12
cost-recovery in, 13.7–13.8
cost savings in, 13.10
costs vs. revenues in, 13.14
course-of-therapy fees in, 13.14
decapitalization of, 13.21
definition of, 13.4
demand and supply in, 13.13
economic issues and, 13.7, 13.22
equity of access in, 13.12–13.17, 13.22
exemptions in, 13.16–13.17
experiences with, 13.4–13.6
external funding for, 13.8–13.9
feasibility assessment for, 13.6–13.7
financial management of, 13.7–13.11, 13.14, 13.17–13.18
financing mechanisms in, 11.2, 11.13–11.15
foreign exchange rates and, 13.9
government funding for, 11.7–11.8, 13.8–13.9, 41.3–41.6
guidelines for, 13.22
health staff preparation for, 13.18–13.19
impact evaluation of, 13.13
implementation planning for, 13.12–13.13, 13.22
income and expense reports for, 41.18
inventory control in, 13.18
kit systems and, 26.8
legal issues in, 13.12
local control of, 13.22
management of, 13.9, 13.17–13.18
media communications about, 13.19
medicine fees in, 13.14–13.15
monitoring, 13.19
monthly sales in, 13.10–13.11
operating budgets for, 13.8, 41.16
opinion surveys for, 13.19
organizational issues in, 13.11–13.12
patients and, 13.14, 13.18–13.19
pilot testing of, 13.13
pipeline calculations for, 13.10
pitfalls and lessons of, 13.19–13.22
planning and implementing, 13.6
political issues and, 13.6–13.7
prescribing patterns in, 13.14
price subsidies in, 13.9
pricing in, 13.13–13.17
procurement in, 13.18
protection mechanisms in, 13.16
public preparation for, 13.18–13.19
quality assurance in, 13.18
rational medicine use in, 13.18
referral systems in, 13.13
revenues in, 13.8, 13.13
selection of medicines in, 13.17–13.18
situation analysis for, 13.6–13.7
start-up financing for, 13.9
supervision and, 13.19
supply management in, 13.11–13.12, 13.17–13.18
user fees in, 13.6–13.7, 13.20–13.22
vertical health programs and, 41.3
RFID. See radio frequency identification
rifampicin, 7.6
right to health, 4.14
risk pooling in insurance, 12.4–12.5
Roll Back Malaria Partnership, 2.6–2.7, 14.7
RTRC. See Regional Technical Resource Collaboration
Rwanda
HIV/AIDS treatment in, 17.15
performance-based financing in, 51.19
pharmaceutical donations in, 15.5
pharmaceutical management in, 36.5
RxSolution (MSH), 50.12

safety of medicines
Institute for Safe Medication Practices (United States), 35.10
perceived, 5.4–5.5
regulation of, 6.10
terms for, 35.6
of traditional medicine, 5.8–5.9, 5.15

security management
batch number registration in, 43.7
breaches in, 43.3–43.5
bribery control in, 43.9–43.11
capsule imprinting in, 43.7
cost of, 43.12–43.13
fraud control in, 43.11–43.12
guidelines for, 42.12–42.13
in health facilities, 43.11, 46.4, 46.7
in hospitals, 43.10–43.11
imprinting packaging for, 43.7
inventory control in, 43.6, 43.8
law enforcement and, 43.9
in medical stores, 43.10, 44.9–44.10, 44.17
order quantities and, 43.11
in outpatient departments, 43.11
in ports, 43.10
selection of medicines and, 43.11
supplier selection and, 43.11
tablet embossing in, 43.7
theft control in, 43.4–43.9
in transport management, 43.10
unique identifiers in, 43.6–43.7
selection of medicines. See medicine selection
semifluid location systems, 44.12
Senegal, 31.8
sensitivity analysis, 10.13
sentinel sites, 48.5–48.6
service level
budget requirements for, 20.4–20.5, 20.26–20.28
to operating units, 23.8–23.11
stock in, 23.8–23.11
severity index for medication errors, 35.14
Shandong province, China, 9.15
shelf life of medicines, 39.9
shelving, 42.14
shipment dates, 39.10
shortage costs, 23.7, 40.8
short-dated products, 23.19
short-list tendering, 42.15
SIAMED, 50.14
Sierra Leone, 43.8
simulated patient surveys, 28.14–28.16
Singapore, 12.17
single-payer insurance, 12.4
single-source medicines, 9.8
site planning, 34.9–34.10, 42.5, 42.8–42.10
situation analysis, 13.6–13.7, 36.4
skimming in insurance, 11.11
small-scale production of pharmaceuticals, 45.12–45.14
SMART objectives
  in management planning, 38.5, 38.13
  in monitoring and evaluation, 48.11
  in training programs, 52.5
smartphones, 50.3
SNMN. See National Insurance for Mothers and Children
social health insurance
  introduction to, 1.13, 11.11
  pharmaceutical benefits in, 12.3–12.4
  rational medicine use in, 12.11–12.12
  supply strategies and, 8.3
social marketing
  communication with consumers and, 33.14
  for rational prescribing, 29.22
  retail drug sellers and, 32.5
social welfare perspectives, 8.5
software
  custom, 50.7
  generally, 50.9–50.14
  general-purpose, 50.5–50.6
  for management information, 49.12
  for networks, 50.7
  open source, 50.7–50.8
  options and guidelines for, 50.5
  for planning, 38.18–38.19
  special-purpose commercial, 50.6
  for supply management, 50.13
South Africa, 5.7, 46.11
South Centre, 3.17
splitting tender awards, 21.7
spoilage costs, 40.6
spreadsheets, 50.6
sputum collection, 47.9
Sri Lanka, 15.7
stability of pharmaceuticals, 19.5
staffing. See also human resources management (HRM)
  for computer use, 50.16–50.17
  for distribution management, 22.15
  in health facilities, 46.12
  in health services contracts, 39.15
  in hospital pharmacies, 45.3–45.4
  for management information systems, 49.12–49.13
  in medical stores, 44.17–44.19
  in medicine information centers, 34.10
  for procurement, 18.19
  in retail drug outlets, 32.11
  in storage facilities, 42.8
  for supply management, 17.3
standard deviations, 23.22–23.23
standard operating procedures, 30.5–30.10
standard performance indicators, 23.7
standard treatment guidelines (STGs)
  benefits of, 17.3
  clinical evidence and, 17.6
  compliance with, 17.9
  contraindications in, 17.7
  costs in, 17.7–17.8
  defined, 17.2
  development of, 17.3–17.9
  diagnostic criteria in, 17.7
  distribution criteria and, 17.14
  drafting, 17.7
  drug information in, 17.9
  first choice treatments in, 17.7
  formulary manuals and. See formulary manuals
  in Ghana, 29.8
  implementing, 17.14–17.15
  indexes in, 17.9
  information in, 17.7–17.9
  investigating medicine use and, 28.6
  levels of care in, 17.4–17.6
  in medicine selection, 16.8–16.10
  for meningitis, 29.8
  monitoring, 17.10
  production issues in, 17.5
  rational medicine use and, 27.12
  rational prescribing and, 29.3, 29.8, 29.15
  referral criteria in, 17.9
  reviewing and editing, 17.7
  side effects in, 17.7
  use of, 17.5, 17.9–17.10
standardization of equipment, 47.5–47.6
Starting or Strengthening a Drug Bulletin: A Practical Manual, 34.14
state wholesale monopolies, 8.3–8.4
sterile production, 45.13–45.14
STGs. See standard treatment guidelines
stock
  accounts of, 41.18
  alphabetizing, 44.13
  arrangement of, 46.6–46.7
INDEX

classifying, 44.12–44.13
cost of maintaining, 46.3
in dispensing practices, 30.6–30.7
disposing of expired or damaged, 44.16
FEFO and FIFO for, 44.8
flow of, 44.5–44.9
in health facilities, 46.9–46.12
in hospital pharmacies, 45.3, 45.8
in kit systems, 26.13
location of, 44.10–44.12
maximum approach to, 46.8
in medical stores. See medical stores management
ordering, 46.7–46.9
placement of, 23.17, 46.4, 46.9–46.12
receipts for, 44.5–44.7
receiving, 46.9
records for, 44.4, 44.21–44.24
rotating, 46.4, 46.6
storing. See storage facilities
unpacking, 46.9
zones for in storage, 44.9–44.10
Stop TB, 2.6, 14.7, 26.4
storage facilities
acquisition of, 42.9
ancillary accommodations in, 42.12
budgeting for, 42.8–42.9
building, 42.5, 42.8
commercial buildings for, 42.8
commissioning of, 42.16–42.17
construction of, 42.13–42.14, 42.16
consultants for planning, 42.5
contracts for procuring, 42.15
conventional procurement of, 42.14
cost of, 22.16–22.17, 42.5–42.6
defects liability in, 42.17
design-and-build model for, 42.5, 42.14
designing, 42.9–42.14
distribution management and, 22.5–22.17, 22.11–22.13
emergency responses and, 42.13
energy efficiency in, 42.11
environmental conservation and, 42.11
equipment in, 42.17
ergonomic considerations in, 42.14
fire protection for, 42.13
glossary of terms, 42.17–42.19
in health facilities, 46.3–46.7
inception phase of, 42.4–42.6
information technology and, 42.12
inventory management and, 23.19
item-by-item analysis of, 42.7
layout of, 42.12–42.13
loading bays in, 42.12
maintenance of, 42.17
manual warehouses, 42.2
materials for, 42.6
mechanical equipment for, 42.13
mechanized warehouses, 42.2
in medical stores, 44.7, 44.13–44.15
needs assessment for, 42.5
open tendering for, 42.15
order value calculations for, 42.7
pallet racking in, 42.13
payments for, 42.16
prefabricated buildings for, 42.4, 42.8, 42.14–42.15
prequalification tendering for, 42.15
production information for, 42.10
project-planning stage for, 42.14–42.16
public-private partnerships for, 42.5, 42.15
quality assurance and, 19.17–19.18
regulatory requirements for, 42.8
schematic designs for, 42.9–42.10
security guidelines for, 42.12–42.13
shelving in, 42.14
short-list tendering for, 42.15
site considerations for, 42.5, 42.8–42.9
size of, 42.6–42.8
special conditions in, 42.12
staff needs in, 42.8
storage methods in, 42.10–42.11
storerooms as, 42.2
supervision of building of, 42.16
telecommunications in, 42.12
temporary buildings as, 42.8
tender for, 42.14–42.16
turnkey model for, 42.5, 42.14–42.15
types of, 42.2, 42.6
valuations for, 42.16
volume of shipments in, 42.7
strategic planning
for laboratory services, 47.4
in pharmaceutical management, 38.2–38.3, 38.6–38.11
in program management, 37.10
for rational medicine use, 27.9–27.14
for training programs, 52.9
Strategies for Enhancing Access to Medicines (SEAM) Program (MSH)
on access indicators, 36.11
and accredited drug-dispensing outlets in Tanzania, 1.16, 32.6–32.8, 32.13–32.14
and CAREshops in Ghana, 1.16, 32.9
in El Salvador, 21.4
on patient counseling, 30.9
pharmaceutical assessments by, 36.9–36.10
quality assurance and, 19.11
supply assessments by, 36.13
supply systems and, 8.11
strength or potency of medicines, 19.4
streptomycin, 2.2
structured observations in qualitative data collection, 28.14–28.16
study tours, 14.10
Studying a Study and Testing a Test, 34.3
substandard medicines, 6.14–6.15
substitutable product use, 28.9
Sudan, 13.3, 15.5
sulfonylureas, 2.2
supervision
field, 48.7
focused, 37.16
in medical stores, 44.17
monitoring and evaluation and, 48.3, 48.8
of pharmaceutical programs, 37.5
of procurement, 18.18
for rational prescribing, 29.8, 29.10
of revolving drug funds, 13.19
of storage facility construction, 42.16
suppliers
qualification and monitoring of, 18.13–18.14
quality assurance by, 19.11–19.12
security and, 43.11
and tender management, 21.10–21.13
supply chains
integrated, 18.8
managing, 40.26
pricing policies and, 9.10–9.13
in service contracts, 39.13
supply management
ABC analysis in, 40.19
contracting services for, 8.13
costs in, 40.5–40.9
critical path method in, 38.17
efficiency in, 40.9
entry points in, 22.12
indicators in, 48.11–48.12
kits in, 26.2
national medicine policies and, 4.7–4.8
pipelines in, 20.10
in revolving drug funds, 13.17–13.18
strategies for. See supply strategies
systems for. See supply systems
treatment guidelines and, 17.3
supply strategies
autonomous supply agencies, 8.7–8.10
capacity in, 8.17
central medical stores in, 8.7
comparison of, 8.6, 8.13–8.14
competition failure in, 8.5
corruption and, 8.17
costs in, 8.17
decentralization in, 8.16–8.18
degination in, 8.16
devolution in, 8.17
direct delivery in, 8.10
distribution systems in, 8.3–8.4
equity in, 8.5
for essential medicines, 8.18
externalities in, 8.5
financing, 8.3–8.4, 8.17
for-profit services in, 8.15–8.16
fully private systems, 8.4
fully public systems, 8.3
government role in, 8.5–8.7
health systems and, 8.16–8.18
information failure in, 8.5
market economy perspectives in, 8.5
not-for-profit services in, 8.14–8.15
primarily private systems in, 8.12
primary distributor systems in, 8.11–8.12
private channels in, 8.14–8.16
private financing of public suppliers in, 8.3
private suppliers of public services in, 8.3
privatization in, 8.17
quality of medicines in, 8.17
retail sales outlets in, 8.15–8.16
social health insurance in, 8.3
social welfare perspectives in, 8.5
state wholesale monopolies in, 8.3–8.4
sustainable changes in, 8.18–8.19
vertical systems in, 8.14
supply systems
assessing. See supply systems assessment
expenditures for pharmaceuticals in, 40.5
private-sector prices and, 40.26
quality assurance in, 19.20
for revolving drug funds, 13.11–13.12
supply systems assessment
approaches to, 36.6–36.8
cost of, 36.8–36.9
data in, 36.14, 36.17–36.19
document reviews in, 36.17
emergent problems in, 36.3
field observation in, 36.17–36.18
functionality in, 36.9–36.12
government commitment in, 36.6
information collection in, 36.10, 36.14–36.18
monitoring interventions and, 36.3
objectives for, 36.6
options analysis in, 36.4
performance indicators in, 36.14–36.15
planning and management of, 36.18–36.19
policy formulation and, 36.3
political mapping in, 36.14
prerequisites for, 36.5–36.6
private-sector capacity in, 36.12–36.13
procedures for, 36.6
qualified teams for, 36.6
qualitative data in, 36.14, 36.18
quantitative data in, 36.14
reasons for, 36.2–36.5
reports on, 36.19
retrospective record review in, 36.17
situational diagnosis in, 36.4
structure of, 36.5–36.9
time frames in, 36.8–36.9
unstructured, 36.6
using results of, 36.19–36.20

sustainability
of access. See access to medicines
donor financing, 14.14
in financing strategies, 11.3–11.4
in supply strategies, 8.18–8.19
SWAp. See sector-wide approach
SWOT analysis, 38.9

tablet embossing, 43.7
Tajikistan, 9.15
Tanga AIDS Working Group (Tanzania), 5.6
Tanzania
access to medicines in, 1.16, 36.11
accredited drug-dispensing outlet program in, 32.13–32.14
consumer education in, 33.9
drug shop accreditation in, 32.6
HIV/AIDS/TB programs in, 12.12, 38.6, 38.13
medication counseling in, 30.9
PDA use in, 50.9
primary health kits in, 22.11, 26.13
quality assurance in, 19.11
supply assessments in, 36.10, 36.13
supply strategies in, 8.11
traditional medicine in, 5.6
tariffs, 7.7, 9.18–9.19
taxes, 9.18–9.19
TB (tuberculosis). See tuberculosis (TB) treatment
Teacher’s Guide to Good Prescribing, 29.6, 34.3
teams
multidisciplinary, 13.12
multisectoral, 38.6
technical assistance, 18.20–18.21
technical cooperation, 4.7, 14.16–14.17
technical efficiency, 10.9–10.10, 11.3
technical expertise, 4.18–4.19, 14.10
technical medicine information, 34.7–34.9
technology transfer, 3.18–3.19
telecommunications, 42.12
temperature control, 44.9–44.10
tender management
accounting in, 21.20
adjudication in, 21.15–21.18
appeal periods in, 21.18
boards for, 18.19
collating offers in, 21.15–21.16
computer reports in, 50.13
defining needs in, 21.9–21.10
documents in, 21.13–21.15
estimated- vs. fixed-quantity contracts in, 21.6–21.7
evaluating suppliers in, 21.28
format and scope of tender in, 21.3–21.9
frequency of, 21.8–21.9
instructions to bidders in, 21.13
international agencies and, 21.12
international laws governing, 21.18
international procurement and, 21.7–21.8, 21.11
international wholesale exporters and, 21.11
invitations to bid in, 21.13
local agents and, 21.7–21.8
local importers and distributors in, 21.11
management information systems in, 21.18
medicine selection in, 21.10
monitoring supplier performance in, 21.13
open periods in, 21.15
open tender offers in, 21.15
pharmaceutical manufacturers and, 21.11
prequalification of suppliers in, 21.12
primary/secondary contracts vs. rebids in, 21.7
primary vs. secondary suppliers in, 21.11
procurement reports in, 21.23
procurement systems in, 21.19–21.24
product records in, 21.19–21.20
purchase orders in, 21.21–21.22
qualified suppliers in, 21.11–21.12
quality assurance in, 21.18–21.20
quantification in, 21.10
records in, 21.19–21.23
requirements in, 21.14–21.15
research- vs. nonresearch-based producers in, 21.11
restricted vs. open tender in, 21.4–21.5
special criteria in, 21.16–21.18
splitting tender awards in, 21.7
for storage facilities, 42.14–42.16
suppliers in, 21.10–21.13
technical specifications in, 21.13–21.14
tender lists in, 21.14–21.15
tertiary production, 7.3
timing in, 21.8–21.9
trial purchases in, 21.13
test data protection, 3.7–3.9, 3.12
test pricing, 13.15
tetracycline, 2.2
Thailand, 9.15, 36.12
thalidomide, 2.3
theft control
in health facilities, 46.5–46.6
In security management, 43.4–43.9
therapeutic category analysis, 18.15, 40.19–40.24
therapeutic classification systems, 16.10–16.13, 44.12
therapeutic equivalence, 3.3, 45.6–45.7
therapeutic windows, 19.16–19.17
therapeutics information. See medicine information
Therapeutics Information and Pharmacovigilance Center (TIPC) (Namibia), 34.11
thrombolytics, 17.8
tiered quality assessments, 19.16–19.17
time management, 37.12
TM. See traditional medicine
tool kit for drug sellers, 32.13
Tools for Planning and Developing Human Resources for HIV/AIDS and Other Health Services, 51.8
top-down planning, 38.5–38.6
total cost analysis, 40.3–40.9
total costs, 10.13, 18.5
Trade-Related Aspects of Intellectual Property Rights. See TRIPS
trade terms (INCO), 39.5–39.6
traditional medicine (TM)
accessibility of, 5.4, 5.8, 5.12
affordability of, 5.4
changing role of, 5.2–5.4
efficacy of, 5.8–5.12, 5.15
government policy on, 5.8–5.9
herbals in, 5.5–5.7
for HIV/AIDS, 5.6
incorrect usage of, 5.5
indigenous knowledge protection in, 5.13–5.14
intellectual property rights in, 5.13–5.14
national health care systems and, 5.9, 5.12–5.13, 5.15
national medicine policies and, 5.10–5.11
perceived safety of, 5.4–5.5
pharmacovigilance in, 5.12
plant protection in, 5.13
providers of, 5.14–5.15
quality of, 5.5, 5.8–5.12, 5.15
rational use of, 5.8, 5.14–5.16
reasons for using, 5.4–5.5
regulation of, 5.8, 5.10–5.12, 5.15, 6.13
research on, 5.15
risks of, 5.5–5.7
safety of, 5.8–5.9, 5.15
Traditional and Modern Health Practitioners Together Against AIDS and Other Diseases (THETA) (Uganda), 5.6–5.7
training programs
audiovisual aids in, 52.9
brainstorming in, 52.6, 52.8
case studies in, 52.6, 52.8
demonstrations in, 52.6, 52.8
in developing countries, 52.10
distance learning in, 52.6
and donor financing, 14.10
for drug and therapeutics committees, 52.10
e-learning in, 52.7–52.8
follow-up activities for, 52.10
group exercises in, 52.7–52.8
implementing, 52.9–52.16
for improving performance, 52.4
for in-country counterparts, 52.11–52.12
learning methods in, 52.6–52.8
lectures in, 52.7–52.8
logistics checklist, 52.20
materials for, 52.7
in medical stores, 44.17
in medicine information, 34.12
monitoring and evaluation of, 52.16
monitoring-training-planning for, 52.11–52.12
by MSH, 52.10, 52.13
needs and knowledge assessments in, 52.4
networks for, 52.13
objectives of, 52.3, 52.4–5.2.5
observation trips for, 52.11
personal style of trainers in, 52.15–52.16
presentations in, 52.15
on quality assurance, 19.20
for rational prescribing, 29.3–29.7
role-playing in, 52.7–52.8
seating arrangements for, 52.14
self-paced, 52.7
sequencing topics in, 52.7
simulation games in, 52.7
SMART objectives in, 52.5
strategies for, 52.9
subject areas in, 52.4–52.5
in supply management, 52.15
by WHO, 52.13
worksheets in, 52.7–52.8
transparency
assessing, 11.10, 36.12
national medicine policies and, 4.14
in procurement, 18.12, 18.15
transport management
alternatives in, 25.5
average drops per vehicle in, 25.13
contracting out, 25.8, 25.14–25.15
costs in, 22.16–22.17, 25.6, 25.14–25.15, 40.6
donation of vehicles in, 25.6–25.8
driver training in, 25.11
fleet mix in, 25.4
fuel in, 25.9
in-house transport in, 25.3–25.6, 25.15
inventory management and, 23.7
lease of vehicles in, 25.8
motorcycles in, 25.11
onboard computers in, 25.10
performance measurements in, 25.6, 25.13–25.14
plans for, 25.5–25.7
private-sector issues in, 25.14
problems in, 22.18
purchase of vehicles in, 25.6
quality assurance and, 25.15–25.17
refrigerated vehicles in, 25.9–25.10
rental of vehicles in, 25.8
route planning in, 25.3–25.5
safety in, 25.16
schedule planning in, 25.3–25.5
temperature control in, 25.9
theft control in, 43.10
vehicle acquisition and disposal in, 25.6–25.10
vehicle capacity usage in, 25.13
vehicle maintenance in, 25.12–25.13
vehicle operating costs in, 25.14
vehicle replacement policy in, 25.8–25.9
vehicle security in, 25.11–25.12
vehicle selection in, 25.9–25.10
vehicle use in, 25.10–25.12
waste products in, 25.13
workshops in, 25.12–25.13
TREAT Program for antiretroviral therapy (Uganda), 47.3
Treatment Action Campaign (TAC) (South Africa), 31.3
treatment guidelines. See standard treatment guidelines
TRIPS (Trade-Related Aspects of Intellectual Property Rights)
access to medicines and, 3.14–3.16
Article 6 of, 3.7
Article 30 of, 3.7
Article 31 of, 3.6–3.7
Article 39.3 of, 3.7, 3.9
Article 40 of, 3.7
Article 70.9 of, 3.9
bilateral trade agreements vs., 3.12
expertise development under, 3.15
history of, 2.10
inability to use, 3.11
key concepts in, 3.5–3.6
national legislation and, 6.3–6.4
pharmaceutical production and, 7.6
regional cooperation under, 3.16
TRIPS-plus provisions, 3.14
using flexibilities of, 3.10–3.11
tsunami relief, 15.7, 26.4
tuberculosis (TB) treatment
community participation in, 31.14
diagnostic kits for, 47.9
distribution challenges for, 22.7–22.8
in the Dominican Republic, 20.7
history of, 2.6–2.7
inaccurate blood tests for, 47.7
medicine use in, 1.5, 33.8
multidrug resistance in, 49.13
and patient kits, 26.4
in Tanzania, 38.6, 38.13
Tunisia, 6.4
turnkey model, 42.5, 42.14–42.15
Uganda
antiretroviral therapy in, 47.3
community-based health insurance in, 12.15
counterfeit medicines in, 19.9
essential supplies and equipment in, 47.11
health facility medicine use in, 28.9
PDA use in, 50.9
retail drug outlets in, 28.18
retail drug seller education in, 32.4
traditional medicine in, 5.6
underuse of medicines, 27.5
UNICEF
Community Integrated Management of Childhood Illness by, 31.6
on disposable syringes, 47.7–47.8
on essential medicines concept, 2.4, 16.3
kit systems by, 26.12
prequalification of suppliers by, 21.5
role in program development, 2.8
Surgical Instruments Supply Kit by, 47.8
unit prices of products, 18.3–18.5, 23.7
UNITAID
for access to medicines, 1.14
for HIV/AIDS medicines and commodities, 2.6
donor financing and, 14.7–14.9
unit-dose medicine distribution, 45.9
United Nations
Children's Fund. See UNICEF
Conference on Trade and Development (UNCTAD), 2.4
and donor financing, 14.8–14.9
history of health agencies of, 2.3–2.4
Industrial Development Organization of (UNIDO), 2.4
Joint United Nations Programme on HIV/AIDS (UNAIDS), 47.6, 51.5
Millennium Development Goals of. See Millennium Development Goals (MDGs)
UNESCO, 51.7
United States
AIDS relief by. See U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
drug use reviews in, 29.14–29.15
Food and Drug Administration of. See Food and Drug Administration (FDA)
international development by. See U.S. Agency for International Development (USAID)
limited medicines lists in, 29.20
medicine use by senior citizens in, 12.10
National Library of Medicine, 50.15
nonformulary medicine use in, 45.8
President’s Malaria Initiative, 1.14
unit of analysis, 28.6
universal health coverage, 12.2–12.3
University of California, Berkeley, 5.14
untrained medicine sellers, 30.15–30.16
U.S. Agency for International Development (USAID)
on human resources crisis, 51.8–51.9
on pharmaceutical assessments, 36.9
pharmaceutical management indicators by, 36.16–36.17
U.S. Code of Federal Regulations, 6.6
U.S. Pharmacopoeia, 19.8
U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)
antiretroviral therapy and, 2.6, 47.3
introduction to, 1.14
quantifying pharmaceutical requirements by, 20.8
use of medications. See medicine use
user fees
for essential medicines, 11.7
in financing strategies, 11.7–11.8
introduction to, 13.2–13.6
local retention of, 13.6–13.7, 13.22
USP Drug Information, 50.16
vaccines, 2.2, 3.18
validating prescriptions, 30.5
variable costs, 10.13
variable item fees, 13.14
variable pricing, 9.10
vehicle usage, 22.14
VEN (vital, essential, nonessential) analysis
essential medicines lists and, 40.12
and expenditures for pharmaceuticals, 40.9–40.13
in inventory management, 23.7
in procurement, 18.15
Venezuela, 6.4
vertical supply systems, 8.14, 41.3
Vietnam, 45.13
Vioxx, 2.10
volume
in distribution management, 22.18
in procurement, 18.12–18.13
in storage facilities, 42.7
voluntary counseling and testing (VCT), 36.4–36.5, 47.14
voluntary licensing, 3.7, 3.9
warehouse management, 44.2. See also storage facilities
waste
cost of, 40.6
eliminating, 1.6–1.7

in inventory management, 23.19
in kit systems, 26.13
website development, 50.16–50.17
WHO. See World Health Organization
WHO Model Formulary, 17.3, 17.12–17.14
WHO Monographs on Selected Medicinal Plants, 5.14
WHO Operational Package for Assessing, Monitoring and Evaluating Country Pharmaceutical Situations, 36.18
wholesale exporters, 21.11
wholesale prices, 9.11
wide area networks (WANs), 50.7
WISN (workload indicator of staffing need), 51.15
Women Fighting AIDS in Kenya, 5.6
word processing, 50.6
work planning, 37.10, 38.2–38.3, 38.14–38.17
World Bank
bidding documents by, 39.9
donor financing and, 14.8–14.10
on national medicine policies, 4.3
on open tender, 18.6
performance bonds by, 39.9
on pharmaceutical production, 7.3–7.4, 7.9
procurement through loans by, 18.21
World Development Report, 36.14
World Health Assembly (WHA), 3.14, 3.17–3.18
World Health Organization (WHO)
on access to medicines, 1.3
on adherence to treatment, 33.4, 33.9–33.10
assessing governance, 1.11
banning inaccurate blood tests for TB, 47.7
certification of products by, 19.14
on childhood illnesses management, 31.6
on classification of diseases, 28.6
on community participation, 31.3
on consumer use of medicines, 28.13
on counterfeit medicines, 19.9
defined daily doses and, 40.24
on diagnosing HIV, 47.6
on diagnostic supplies, 47.11
on disposable syringes, 47.7–47.8
on DOTS strategy, 33.11
on drug bulletins, 34.14
drug donation guidelines of, 15.5–15.6, 15.8
equipment specifications of, 47.15–47.17
don essential medicines concept, 1.2, 1.7, 2.3, 2.8
defined daily doses and, 40.24
drug donation guidelines of, 15.5–15.6, 15.8
emergency health kits of, 26.3
equipment specifications of, 47.15–47.17
don essential medicines concept, 1.2, 1.7, 2.3, 2.8
defined daily doses and, 40.24
essential medicines lists of. See Model List of Essential Medicines
Global Initiative on Health Technologies of, 47.3–47.4
Good Governance for Medicines of. See Good Governance for Medicines
on good manufacturing practices, 19.13
history of, 2.3–2.4
on human resources crisis, 51.4–51.9
Intergovernmental Working Group on Public Health, Innovation and Intellectual Property of, 3.17
on medical products and the Internet, 34.3
medicine information of, 34.14
on medicine promotion, 34.8
medicine selection criteria of, 16.5
on medicine use communications, 33.21
on medicine use in health facilities, 28.7–28.9
medicine use indicators of, 28.7–28.9
on mortality rates, 1.3–1.4
on national medicine policies, 4.3
organizational roles of, 2.8
pharmaceutical management indicators of, 36.16–36.17
on pharmaceutical production capacities, 7.4
pharmaceutical situation indicators of, 36.15
pharmacopoeia of, 19.4
on pharmacovigilance, 35.2
Pharmacy Education Taskforce Action Plan, 51.7
prequalification of medicines by, 19.12
on prequalification of suppliers, 21.4–21.5, 21.12
price monitoring method of, 9.14–9.15
Programme for International Drug Monitoring, 35.10
on quantifying pharmaceutical requirements, 20.8, 20.18
on rational medicine use, 4.16, 27.2
on rational prescribing, 29.6
on social health insurance, 1.13
software by, 50.6
on storage facility planning, 42.7
on traditional medicine, 5.2
training programs of, 52.13
TRIPS and. See TRIPS (Trade-Related Aspects of Intellectual Property Rights)
World Health Report, 31.3
World Intellectual Property Organization (WIPO), 3.14, 3.17
World Trade Organization (WTO)
on fraud, 43.12
on generic medicines, 9.8
on intellectual property, 3.4–3.11, 3.17
on patents, 39.10
pharmaceutical prices and, 9.19
TRIPS Agreement. See TRIPS (Trade-Related Aspects of Intellectual Property Rights)
Yemen, 4.17
Zambia
compulsory license in, 3.8
HIV/AIDS treatment in, 47.14
medication safety form in, 35.13
pharmacovigilance in, 35.13
transport management in, 25.4
Zimbabwe
dispensing prescribers in, 27.8
supervisory visits in, 48.8
transport management in, 25.15
zoning stock, 44.9–44.10